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8TIIVISTELMÄ, Finnish Summary
D-vitamiini on elimistölle välttämätön vitamiini. D-vitamiinia muodostuu iholla
auringon ultraviolettisäteilyn avulla sekä sitä saadaan ravinnosta. D-vitamiini muuttuu
maksassa 25-hydroksi- D-vitamiiniksi (25(OH)D), joka on pääasiallinen veressä
kiertävä muoto ja sen jälkeen munuaisissa aktiiviseksi 1,25-hydroksi D-vitamiiniksi
(1,25(OH)D), joka toimii kalsium- ja fosfaattiaineenvaihdunnan säätelijänä. D-
vitamiinin kuljettajaproteiini (DBP) kuljettaa D-vitamiinimuotoja verenkierrossa ja
kohdekudoksiin. Pieni määrä D-vitamiinia on myös vapaana verenkierrossa. Vapaan D-
vitamiinin on ehdotettu olevan pienestä pitoisuudestaan huolimatta aktiivisempi muoto,
koska se pääsee soluihin ilman reseptoria. DBP:n kyky sitoa 25(OH)D:ta vaihtelee
DBP:n genotyypin mukaan ja voi vaikuttaa siten proteiiniin sitoutuneen ja vapaan
25(OH)D:n pitoisuuksiin veressä. Tutkimuksissa on havaittu, että lihavilla on
alhaisemmat seerumin D-vitamiinipitoisuudet kuin normaalipainoisilla. D-vitamiinilla
on tärkeä rooli luun kasvussa ja luuston ylläpidossa koko ihmisen elinkaaren. D-
vitamiinin puutos lapsuudessa ja nuoruudessa voi vaikuttaa luuston kehitykseen ja
kasvuun. Aikuisuudessa D-vitamiinin puutos voi olla osallisena luukatoon. DBP:n
deglykosyloituneella muodolla on raportoitu olevan rooli luun muodostumisessa.
Tämän väitöskirjan tavoite oli tutkia DBP:n geneettisen vaihtelun vaikutusta D-
vitamiiniaineenvaihduntaan ja luustoon.  Lisäksi tavoite oli tutkia eroaako lihavien D-
vitamiiniaineenvaihdunta normaalipainoisista ja onko mahdollisilla eroilla vaikutuksia
luustoon.
Tutkimusaineisto koostuu 233 suomalaisesta lapsesta ja nuoresta (7–19 vuotiaita)
(Osatyö I), sekä 622 suomalaisesta naisesta ja miehestä (37–47 vuotiaita) (Osatyöt II ja
III). Osatyössä III naiset ja miehet jaettiin painoindeksin mukaan normaalipainoisiin,
ylipainoisiin ja lihaviin. Kaikissa tutkimuksissa kerättiin D-vitamiinin ja kalsiumin
saantitiedot sekä tietoa lääkityksistä sekä fyysisestä aktiivisuudesta.
Paastoverinäytteestä määritettiin 25(OH)D, lisäkilpirauhashormoni (PTH), albumiini
sekä luun aineenvaihdunnan merkkiaineet. Lisäksi määritettiin DBP:n pitoisuudet
(osatöissä II - III) sekä sen geenipolymorfioita (osatyöt I ja II). Vapaan 25(OH)D:n
pitoisuudet määritettiin laskennallisesti (osatöissä II ja III) ja lisäksi tutkimuksessa II
25(OH)D pitoisuudet vakioitiin genotyyppikohtaisilla affiniteettivakioilla. Luun
mineraalitiheys mitattiin kaksienergiaisella röntgenabsorptiometrialla (DXA) (osatyö I)
ja perifeerisellä kvantitatiivisella kerroskuvausmenetelmällä (pQCT) (osatyöt I ja III).
9Lapsilla ja nuorilla (Osatyö I) DBP:n genotyypillä GC 2/2 oli matalimmat 25(OH)D ja
PTH-pitoisuudet. Pojilla DBP:n genotyyppi oli negatiivisesti yhteydessä lonkan luun
mineraalipitoisuuteen ja lannerangan luun mineraalitiheyteen. Molemmilla sukupuolilla
DBP:n genotyyppi oli yhteydessä lannerangan luun mineraalipitoisuuteen ja luun
vahvuusindeksiin. Aikuisilla (Osatyö II) DBP:n sekä kokonais- ja vapaan 25(OH)D:n
sekä PTH:n pitoisuudet erosivat merkitsevästi DBP:n genotyyppien välillä. DBP:n
pitoisuus oli alhaisin genotyypillä GC2/2. Matalimmat 25(OH)D pitoisuudet havaittiin
diplotyypeillä GC1S/2, GC1S/1F ja GC 2/2. Käytettäessä genotyyppiadjustoituja arvoja,
genotyypillä GC2/2 havaittiin korkeimmat vapaan 25(OH)D:n pitoisuudet. Yllättäen
PTH pitoisuus oli myös matalin genotyypillä GC2/2. Osatyössä III lihavilla naisilla oli
matalammat vapaan 25(OH)D:n pitoisuudet kuin normaalipainoisilla. Miehillä sekä
sitoutuneen, että vapaan 25(OH)D:n pitoisuudet olivat matalammat lihavilla kuin
normaalipainoisilla. DBP- ja PTH-pitoisuudet olivat korkeammat lihavilla naisilla
verrattuna normaalipainoisiin naisiin. Yhdistettäessä naisten ja miesten ryhmä, lihavien
ryhmällä oli myös korkeammat DBP- ja PTH-pitoisuudet kuin normaalipainoisilla.
Lihavilla naisilla 25(OH)D oli negatiivisesti yhteydessä hohkaluun tiheyteen
värttinäluussa ja kuoriluun lujuusindeksiin sääriluussa. Lisäksi vapaan 25(OH)D:n
pitoisuudet olivat lihavilla käänteisessä yhteydessä värttinäluun distaalipään
lujuusindeksiin, värttinäluun proksimaalipään tiheyteen kuoriluussa sekä sääriluun
proksimaalipään tiheyteen kuoriluussa.
Saadut tulokset osoittavat, että DBP:n geneettinen vaihtelu vaikuttaa sekä vapaan, että
sitoutuneen seerumin 25(OH)D:n pitoisuuksiin sekä DBP:n ja PTH:n pitoisuuksiin.
Havainnolla voi olla merkitystä, kun D-vitamiinitilaa sekä sen metaboliaa ja toimintoja
tutkitaan. DBP:n geneettinen vaihtelu voi olla yksi tekijä, joka vaikuttaa luumassan
kertymiseen nuoruudessa. Lihavuuden yhteys sitoutuneen- ja vapaan 25(OH)D:n,
DBP:n ja PTH:n pitoisuuksiin viittaavat siihen, että lihavien D-vitamiiniaineenvaihdunta
eroaa normaalipainoisten aineenvaihdunnasta. Muutokset D-vitamiinin
aineenvaihdunnassa voivat vaikuttaa negatiivisesti luustoon.
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ABSTRACT
Vitamin  D  is  a  crucial  vitamin  for  the  human  body.  Vitamin  D  can  be  derived  from
ultraviolet light -induced synthesis in the skin and from the diet. Vitamin D is
metabolized in the liver to the main circulating form, 25-hydroxyvitamin D (25(OH)D),
and then in the kidney to 1,25-dihydroxyvitamin D (1,25(OH)D), which is the endocrine
regulator of calcium and phosphate homeostasis. Vitamin D binding protein (DBP)
transports vitamin D in the circulation and into target tissues. A small amount of vitamin
D is free in the circulation. Hence, these free metabolites have been suggested to be more
active  because  they  can  enter  the  cells  without  a  receptor.  Genetic  variation  of  DBP
coding gene affects the protein’s ability to bind 25(OH)D, thereby influencing DBP
bound and free 25(OH)D concentrations in the circulation. Several studies have reported
that vitamin D concentrations are lower in obese individuals than in their normal-weight
peers. Vitamin has a significant role in bone growth and for maintenance of the skeleton
throughout life. Vitamin D deficiency in childhood and adolescence affects bone
development and growth. In adulthood, vitamin D deficiency can contribute to bone loss.
The deglycosylated form of DBP has been reported to have a role in bone formation.
The purpose of this thesis was to investigate genetic variation of DBP on vitamin D
metabolism and bone. Other goals were to study whether obese individuals differ in their
vitamin D metabolism from the normal-weight individuals and do these potential
differences affect bone.
The study population consisted of 233 Finnish children and adolescents (7-19 years)
(Study I) and 622 Finnish women and men (37–47 years) (Studies II and III). In Study
III, the adults were stratified by body mass index into normal-weight, overweight, and
obese.
The data on dietary intake of vitamin D and calcium, medications and physical activity
were collected. 25(OH)D, PTH, albumin, and bone turnover markers were determined
from fasting blood samples. In addition, DBP concentration (Study II- III) and DBP gene
polymorphisms (Study I and II) were determined. Free 25(OH)D concentrations were
calculated (Study II - III) and in Study II the values were adjusted with genotype specific
affinity values. Bone mineral density was measured with Dual-Energy X-ray-
absorptiometry (DXA) (Study I) and peripheral quantitative computed tomography
(pQCT) in (Study I-III).
11
In children and adolescents (Study I), 25(OH)D and PTH concentrations were lowest in
genotype GC2/2. In boys, DBP genotype was negatively associated with hip bone
mineral content and lumbar spine bone mineral density. In both girls and boys, DBP
genotype was associated with lumbar spine bone mineral content and strength strain
index. In adults (Study II), significant variation were found among DBP gene variants
among DBP, total, free, and bioavailable 25(OH)D, and PTH. DBP concentration was
lowest in genotype GC2/2. 25(OH)D concentrations were lowest in GC diplotypes 1S/2,
1S/1F, and 2/2, but free and bioavailable 25(OH)D concentrations were highest in GC2/2
when a genotype-specific binding constant was used. Unexpectedly, the same gene
variant was also associated with low PTH concentrations.
In Study III, free and bioavailable 25(OH)D concentrations were lower in obese women
than in normal-weight women. In men, both bound and free 25(OH)D were lower in
obese individuals than in those of normal-weight. In addition, DBP and PTH were higher
in obese women and when men and women were combined in the same group.  In obese
women, 25(OH)D was negatively associated with distal radius trabecular density and
tibial shaft cortical strength index (CSI). Furthermore, free and bioavailable 25(OH)D
were negative determinants of distal radius CSI, radial shaft cortical density, and tibial
shaft CSI. Bioavailable 25(OH)D negatively associated with distal radius CSI, radial
shaft cortical density, and tibial shaft CSI among obese subjects.
In conclusion, genetic variation in DBP coding gene is associated with DBP bound and
unbound 25(OH)D, DBP and PTH concentrations. This finding may be relevant, when
vitamin D status, metabolism, and actions are investigated. In addition, the results show
also  that  genetic  variation  of  DBP  can  be  one  factor  affecting  bone  mass  accrual  in
adolescence.
Associations of body mass index with total, free and bioavailable 25(OH)D, DBP, and
PTH concentrations demonstrate a difference in vitamin D metabolism between obese
and normal-weight individuals. Furthermore, altered vitamin D metabolism may have a
negative influence on bone.
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ALP, alkaline phosphatase
ANCOVA, analysis of covariance
ANOVA, analysis of variance
BALP, bone specific alkaline phosphatase
BMC, bone mineral content
BMD, bone mineral density
BMI, body mass index
BSI, bone strength index
Ca, calcium
C5a, complement component 5a
CLIA, chemiluminescence assays
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DEQAS, vitamin D external quality assessment scheme
DBP, vitamin D binding protein
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DXA, Dual Energy X-ray Absorptiometry
ELISA, Enzyme Linked Immunosorbent assay
FFQ, Food Frequency Questionnaire
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FGF23, fibroblast growth factor 23
GC gene, vitamin D binding protein coding gene
GC-globulin, group-specific component, vitamin D binding protein
GC-MAF, GC protein-derived macrophage activating factor
GWAS, Genome-Wide Association Study
1,25(OH)D, 1,25-hydroxy-vitamin D3, calcitriol
25(OH)D, 25-hydroxy-vitamin D, calcidiol
HPLC, high-performance liquid chromatography
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PTH, parathyroid hormone
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RIA, radioimmunoassay
SISU, Sequencing Initiative Suomi
SNP, single nucleotide polymorphism
SSI, strength strain index
TraD, trabecular density
UVB, ultraviolet B
VDSP, Vitamin D Standardization Program
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1 INTRODUCTION
Vitamin  D  has  received  attention  in  many  research  areas  in  recent  years.  Vitamin  D
deficiency is common worldwide and has been suggested to be associated with such
diseases as cancer, autoimmune disorders, hypertension, metabolic syndrome, and
diabetes (Holick et al. 2008, Cashman et al. 2016). Vitamin D status is influenced by
several factors such as sunshine exposure, diet, latitude, and genetic factors (Holick
2008, Wang 2010).
In Finland, vitamin D deficiency has earlier been common both due to low dietary
vitamin D intake (Lamberg-Allardt et al. 2001, Männistö et al. 2002) and to limited
ultraviolet B-radiation (UVB) radiation during winter needed for dermal synthesis of
vitamin D.  Inadequate vitamin D status (25(OH)D < 40 nmol/L) was recognized to be
a potential public health problem among healthy adults in Finland (Lamberg-Allardt et
al. 2001). Vitamin D status of the Finnish adult population has improved considerably
from 2000 to 2011, mostly due to fortification of fluid milk products and increased use
of vitamin D supplements (Jääskeläinen et al. 2017).
Vitamin D is a fat-soluble vitamin produced in the skin by UVB-radiation or obtained
from certain  foods  and  supplements.  The  circulating  form of  vitamin  D,  25(OH)D is
produced in the liver and is converted to the active form known as 1,25-
dihydroxyvitamin D (1,25(OH)D) mostly in the kidney. 1,25(OH)D can also be made in
several other extrarenal sites. Vitamin D binding protein (DBP) transports vitamin D in
the circulation.  Only a small proportion of vitamin D is free in the circulation (Bikle et
al. 1986). The megalin/cubilin receptors at the cell surface take up 25(OH)D/DBP
complex into renal proximal cells. 25(OH)D has commonly been considered the best
biomarker of vitamin D status. However, studies have suggested that unbound, free
25(OH)D could be the more active form of vitamin D (Al Oanzi et al. 2006, Chun et al.
2014, Johnsen et al. 2014, Powe et al. 2011).
Vitamin D, i.e. 1,25(OH)D has important roles in calcium homeostasis.  The most
important one is the regulation of intestinal calcium absorption - 1,25(OH)D increases it
when more calcium is needed in the body. Other mechanism in which 1,25(OH)D is
involved in a hypercalcemic situation includes calcium reabsorption in nephrons and
stimulation of osteoblasts to activate osteoclasts to resorb bone to raise serum calcium
concentration. Vitamin D also suppresses parathyroid hormone (PTH) production, which
also has important roles of its own in calcium homeostasis, by affecting both calcium
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renal reabsorption and bone resorption. Variation in the DBP coding gene can affect
vitamin D status (Arnaud & Constans 1993). In vitamin D deficiency, low intestinal
calcium absorption leads to lower serum calcium concentrations followed by higher PTH
concentrations, which increases bone resorption. This has been suggested to enhance the
development of osteoporosis.
Vitamin D is an important factor for bone health and preventing osteoporosis. In women
bone loss increases especially around menopause due to decreasing oestrogen
concentrations. In men the bone loss is steadier. DBP has been associated with bone
mineral density (BMD) through the genetic polymorphism that can influence the binding
and transport of 25(OH)D and other metabolites in the circulation. It has also been
suggested that DBP could work directly as a precursor protein for macrophage activating
factor (GC-MAF), which activates osteoclasts (Yamamoto 1993, Schneider 1995).
Childhood and adolescence are perhaps the most important phases for bone
development. Low peak bone mass can negatively affect bone remodelling and increase
the risk of having osteoporosis in older age.
Obesity is a worldwide problem and it is often associated with many other diseases such
as metabolic syndrome and insulin resistance (WHO 2000). Obesity has also been
associated with vitamin D deficiency most likely due to the sequestration of vitamin D
in fat tissue (Vanlint 2013).
This  study  aims  to  investigate  the  genetic  polymorphisms  of  DBP  and  vitamin  D
metabolism in Finnish children and adolescents as well as in Finnish middle-aged
subjects and the associations of vitamin D and genetic polymorphisms of DBP with bone
health.  The  first  two  studies  investigate  the  DBP  gene  polymorphism  and  calcium
homeostasis and bone health. The third study focuses on vitamin D metabolism in obese
middle-aged men and women and the effect of free vitamin D metabolites on bone
health. The principal focus of these studies is on investigating the several roles of vitamin
D binding protein in vitamin D status and bone parameters. A future goal is detecting
individuals who are at higher risk of developing vitamin D deficiency.
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2 REVIEW OF THE LITERATURE
2.1 Vitamin D
2.1.1 Sources and current and past recommendations
Vitamin D3 (cholecalciferol) is produced from 7-dehydrocholesterol in the skin during
sunlight i.e. UVB exposure which is the physiological route for vitamin D in humans.
However, food derived vitamin D is important, when sunlight is not always available.
Major natural dietary sources of vitamin D3 are of animal origin, such as many species
of fish, animal and fish liver and inner organs, and egg yolk. Some plant-based dietary
sources, containing vitamin D2 (ergocalciferol), such as wild mushrooms, can  be
produced in baker´s yeast and cultivated mushrooms upon UVB irradiation. Fortified
foods are important dietary sources in many countries, for instance, milk and fat spreads
are fortified with either vitamin D3 or vitamin D2. The ministry of Trade and Industry in
Finland recommended by decree voluntary fortification of some specific food stuffs in
2003: fluid milk products (i.e. milk, sour milk, yoghurt and their non-milk equivalents)
could be fortified with 0.5 ȝg vitamin D3/100 ml and all fat spreads with 10 ȝg/100 g. In
2010, the recommendation for the fortification increased to 1 μg vitamin D3/100 ml and
20μg/100g for fluid milk products and spreads, respectively.
The daily recommendation for vitamin D intake from food and supplements set by the
Finnish  National Nutrition Council was 7.5 μg for persons aged 3-60 years between
2004 and 2013 and from 2014 on 10 μg for children and adolescents (2-18 years) and 10
μg for adults (18-74 years) based on the recommendations of the Nordic Council of
Ministries from 2004 and 2012, respectively (Nordic Council of Ministries 2004,
National Nutrition Council 2005, National Nutrition Council 2014, Nordic Council of
Ministers 2013).
The Institute of Medicine of USA (IOM) 2011 thresholds for serum 25(OH)D
concentrations are  30 nmol/L=vitamin D deficiency, 30–49.9 nmol/L=insufficiency,
and 50 nmol/L=sufficiency (IOM 2011). Many clinicians agree that clinical vitamin D
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deficiency only occurs when serum 25(OH)D is lower than 25 or 30 nmol/L (Lips 2001,
Need et al. 2008, EFSA 2016). There are several different views on optimal serum
25(OH)D concentrations for skeletal effects and muscle strength and non-classical
effects. According to the IOM, the concentration should be at least 50 nmol/L (EFSA
2016) but according to the Endocrine Society at least 75 nmol/L (Holick et al. 2011).
According to Jääskeläinen and colleagues, vitamin D status of the Finnish adult
population has improved significantly from 2000 to 2011 based on the Health 2000 and
2011 studies (Jääskeläinen et al. 2017). Based on their study, 91 % of supplement
nonusers in Health 2011 study, who consumed fluid milk products, fat spreads, and fish
based on Finnish nutrition recommendations reached vitamin D status that is considered
sufficient (25(OH)D  50 nmol/L). Food fortification, especially of fluid milk products,
and increased use of vitamin D supplements are likely reasons for the improvement in
vitamin D status.
2.1.2 Vitamin D metabolism
Vitamin D is a common name for a group of substances, the most important of which
are cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2).  Vitamin D belongs to
a subclass  of  seco-steroids,  with a  structure similar  to  that  of  steroids.  UVB radiation
converts 7-dehydrocholesterol (provitamin D) to previtamin D3, which is isomerized into
vitamin D3. Clothing and sun-screen as well as melanin in the skin blocks UVB radiation
and limits dermal vitamin D production. There is a difference in the intensity of UVB
radiation depending on the season and latitude. Vitamin D3 synthesized in the skin is
transported in blood bound to vitamin D binding protein. Ingested vitamin D2 and D3 are
absorbed primarily in the ileum and transported in chylomicrons and lipoproteins via
lymphatic vessels with other fats, and emptied into the thoracic duct (Vieth 1999).
Vitamin D metabolism is described in Figure 1.
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25-hydroxyvitamin D
Vitamin D is hydroxylated with vitamin D 25-hydroxylase (CYP2R1) into 25(OH)D in
the liver and other tissues (Bikle 2014).  In the circulation, DBP binds up to 90 % of the
25(OH)D (Bikle et al. 1986, Nykjaer et al. 1999). Serum 25(OH)D concentration is
considered  the  best  marker  for  vitamin  D  status  of  the  body.  It  has  three  structurally
different forms: 25(OH)D3, 25(OH)D2, and 3 epi-25(OH)D2/3 epi-25(OH)D3. Megalin is
a transmembrane protein that functions as a cell-surface receptor for the DBP-25(OH)D
complex. When the DBP-25(OH)D complex binds to megalin, 25(OH)D is released and
enters the proximal tubular cells of the kidneys and some other cells through endocytosis
(Nykjaer et al. 1999). 25(OH)D is transformed into 1,25(OH)2D3 or 1,25(OH)2D2 mainly
in the kidney, but also in other tissues. Serum 25(OH)D has much longer half-life (1-2
months) than 1,25(OH)D (4 hours) and is therefore relatively stable. The concentration
of serum 25(OH)D is almost 1000-fold of that of 1,25(OH)D (Lips 2007).  Serum
concentrations  of  25(OH)D  correlate  better  with  a  number  of  clinical  outcomes  (e.g.
cancer rates, immune function, cardiovascular health, and mortality) than serum
1,25(OH)D concentrations (Holick et al. 2008).

1,25-hydroxyvitamin D
25(OH)D is converted into an active vitamin D metabolite, 1,25(OH)D, in the kidney
and  various  other  cells  e.g.  epithelial  cells  of  the  skin,  lungs,  breast,  intestine,  and
prostate; endocrine cells of the parathyroid gland, pancreatic islets, thyroid, testes, ovary,
and placenta; macrophages; T and B lymphocytes and dendritic cells and bone cells,
including osteoblasts and chondrocytes (Bikle et al. 2014). Compared to 25(OH)D,
1,25(OH)D has a very short lifespan. It is an important regulator of calcium homeostasis
and is responsible for the mineral balance of the skeleton. The production of 1,25(OH)D
is regulated by a negative feedback system, where PTH stimulates and calcium,
phosphate, and fibroblast growth factor 23 (FGF23) inhibit its production. When the
concentration of calcium in the circulation falls, PTH is released by the parathyroid
gland. PTH stimulates 25-hydroxyvitamin D 1-alpha-hydroxylase (CYP27B1) to make
more 1,25(OH)D from 25(OH)D. Thus, elevated calcium suppresses CYP27B1 via
suppression of PTH, and elevated phosphate suppresses CYP27B1 by stimulating
FGF23.  1,25(OH)D  binds  to  vitamin  D  receptor  (VDR)  inside  cells  and  induces  the
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absorption of calcium and phosphate in the epithelium of the small intestine. The
increase of 1,25(OH)D causes an increase in calcium transport within the intestine, bone
and kidney and thus, plasma calcium levels rise. The calcium sensing receptor of the
parathyroid gland senses the increased levels of calcium in plasma and the secretion of
PTH is suppressed. 1,25(OH)D can also directly suppress the secretion of PTH (Bikle
2012).
Figure 1 Vitamin D metabolism and actions. Vitamin D is ingested in the diet or produced in the
skin  with  exposure  to  UVB  radiation.  DHCR7  converts  7-dehydrocholesterol  into  vitamin  D.
Vitamin D (D2 or D3) is converted by CYP2R1 to 25(OH)D in the liver. 25(OH)D is converted
by CYP27B1 to 1,25(OH)D in the kidneys and several other cells. 1,25(OH)D increases intestinal
calcium and phosphorus absorption and stimulates osteoblast and osteoclast production in bone.
In the parathyroid glands, 1,25(OH)D decreases PTH synthesis and release. Modified from
(Holick 2006).
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Assessment of 25(OH)D
A hydrophobic nature, three structurally different forms, and tight binding to DBP render
measurement of 25(OH)D challenging (Binkley & Carter 2017). There are several
methods to determine 25(OH)D in serum such as high-performance liquid
chromatography with UV detection (HPLC/UV), liquid chromatography–tandem mass
spectrometry (LC-MS/MS), and immunoassays (radioimmunoassay (RIA), competitive
protein-binding assays (CPBA), enzyme-linked immunosorbent assays (ELISA),
chemiluminescence assays (CLIA). Liquid chromatography, followed by LC-MS/MS is
more precise than immunoassays and has therefore become the gold standard for the
measurement of vitamin D. With these two methods, it is possible to measure 25(OH)D3
and 25(OH)D2 separately.  They  can  also  detect  other  vitamin  D  metabolites  such  as
24,25-dihydroxyvitamin D (24,25(OH) D). LC-MS/MS analyses have revealed that
immunoassays are marred by interference of 24,25(OH)2D, particularly at higher
25(OH)D concentrations. This leads to excessive 25(OH)D concentrations in the
analysis (Binkley & Carter 2017). Furthermore, the 3-epi-25(OH)D metabolite may
interfere in some immunoassays (Bailey et al. 2014, Binkley & Carter 2017,
Calvo&Lamberg-Allardt 2017).
The  Vitamin  D  External  Quality  Assessment  Scheme  (DEQAS)  was  founded  to
guarantee the analytical reliability of 25(OH)D and 1,25(OH)D assays. DEQAS has
revealed substantial differences among different vitamin D measurement methods both
within and between laboratories.  DEQAS has distributed serum to around 1200
laboratories. Participating laboratories receive the results as the difference between their
laboratory and the overall mean value (http://www.deqas.org/, Carter 2010). The
Vitamin D Standardization Program (VDSP) was established in 2010 by the National
Institutes of Health Office of Dietary Supplements in USA. VDSP is an international
collaboration and its purpose is to standardize the measurements of vitamin D status
among different laboratories. The aim is to have comparable laboratory measurements
of vitamin D over time, location, and laboratory procedure (Binkley et al. 2014,
Cashman et al. 2015).
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2.1.3 Genes related to vitamin D metabolism
Genome-Wide Association Studies (GWAS) and candidate gene studies have identified
several genes involved in vitamin D synthesis, metabolism and transport (Shea et al.
2009, Ahn et al. 2010, Wang et al. 2010). Genetic variation in GC (vitamin D binding
protein), CYP2R1 (Vitamin D 25-hydroxylase), 7-dehydrocholesterol reductase
(DHCR7), CYP24A1 (1,25-dihydroxyvitamin D 24-hydroxylase), 1Į-hydroxylase
enzyme (CYP27B1, and VDR coding genes has been associated with vitamin D status
(Engelman et al. 2008, Wang et al. 2010). DHCR7 coding gene is located on
chromosome 11q13.4. DHCR7 enzyme catalyses the production of cholesterol from
dehydrocholesterol and can control the amount of available 7-dehydrocholesterol for
previtamin D synthesis. CYP2R1 coding gene is located in chromosome 11p15.2 and it
encodes the enzyme vitamin D 25-hydroxylase in humans. It is a member of the
cytochrome P450 enzyme family. The enzyme converts vitamin D3 into 25(OH)D in the
liver. A mutation in the CYP2R1 gene leads to amino acid substitution and eliminates
the enzyme activity and is associated with low circulating levels of 25(OH)D and vitamin
D deficiency (Cheng et al. 2004). CYP27B1 is a gene coding the 1Į-hydroxylase enzyme
that  converts  vitamin D to its  active form 1,25(OH)D in the kidney and is  located on
chromosome 12q14.1. CYP24A1 gene encodes the mitochondrial 1,25-
dihydroxyvitamin D3 24-hydroxylase enzyme. CYP24A1 gene is located on chromosome
20q13.2 and takes part in the degradation of 25(OH)D and 1,25(OH)D (Jones et al.
2012). VDR gene encodes vitamin D receptor (Issa et al. 1998, Brown et al. 1999). VDR
is a nuclear transcription factor that regulates the transcription of vitamin D target genes.
It belongs to the nuclear hormone receptor superfamily (Bouillon et al. 1998, Issa et al.
1998). VDR is activated when a ligand 1,25(OH)D, is bound to it.  Furthermore, VDR
heterodimerizes with other nuclear receptors and binds to specific DNA sequences in the
promoter region of vitamin D target genes (Saccone et al. 2015). VDR genes  are
expressed  in  almost  all  tissues  in  the  human  body  and  can  regulate  the  expression  of
hundreds of genes (Bikle 2014).
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2.2 Free 25(OH)D
Most  of  the  circulating  vitamin  D  metabolites  are  bound  to  DBP  (85%)  and
approximately 15% to albumin. Only 0.4% of 1,25(OH)D and 0.03% of 25(OH)D is free
in serum. Bioavailable 25(OH)D comprises of the free fraction and the fraction bound
to albumin. According to the free hormone hypothesis, only hormones that are not bound
to binding protein, such as vitamin D metabolites, sex steroids, cortisol, and thyroid
hormone, are able to enter cells and have biological effects there (Mendel 1989). Vitamin
D can enter the cells bound to DBP through megalin/cubilin receptor or through the cell
membrane with passive diffusion of the free 25(OH)D (Nykjaer 1999). The
concentration of free 25(OH)D is in equilibrium with the DBP-bound 25(OH)D, and the
concentration of both bound and free forms are dependent on DBP and albumin
concentrations. The in vivo studies in mice that lack DBP supported the hypothesis that
free 25(OH)D and 1,25(OH)2D concentrations are biologically more important than total
concentrations. DBP-null mice maintained normal calcium homeostasis when fed a
vitamin D-rich diet and had no evidence of bone disease despite having very low levels
of circulating 25(OH)D and 1,25(OH)2D (Safadi et al. 1999). When DBP was added to
keratinocyte, monocyte, or osteoblast cultures, or to kidney homogenates or bone tissue
cultures, it inhibited cellular uptake and actions of vitamin D metabolites (Chun et al.
2014). Several clinical studies have shown that estimated free and bioavailable 25(OH)D
are more strongly associated with BMD (Powe et al. 2011), PTH, serum calcium (Bhan
2014), and osteoporosis (Al-Oanzi et al. 2006) than total 25(OH)D.
2.2.1 Calculated vs. measured value of free 25(OH)D
There are different methods for measuring free and bioavailable 25(OH) concentration.
Many  studies  have  used  calculation  of  free  25(OH)D.  The  calculation  of  free  and
bioavailable 25(OH)D concentrations is based on a mathematical formula that takes into
account  total  25(OH)D,  DBP,  and  albumin  concentrations  as  well  as  their  affinity
constants (Bikle et al. 1986). The calculation has some challenges: the formula uses the
measured concentrations of DBP and 25(OH)D and is therefore dependent on the
accuracy of the measurement of both 25(OH)D and DBP concentrations.  The results of
DBP assays differ depending on the assay. In addition, it presumes that the interaction
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between 25(OH)D and DBP variants is similar in vivo to in vitro binding affinity binding
constants. Earlier studies that measured affinity binding constants of several DBP
variants under different conditions obtained inconsistent results depending upon the
buffering agent used (Chun et al. 2010, Powe et al. 2013, Johnsen et al. 2014).
Also, a direct two-step immunoassay for quantifying free 25(OH)D has been developed.
This assay is dependent on the quality of the antibody used to bind the free 25(OH)D.
The measurement of free 25(OH)D and 1,25(OH)D is difficult because of their very low
concentrations and physico-chemical behavior. The assay recognizes 25(OH)D2 less
well than 25(OH)D3 (approximately 77%) and may, therefore, underestimate the free
25(OH)D2, but under most situations in which the predominant vitamin D metabolite is
25(OH)D3, the data compare well with those obtained from similar populations using the
centrifugal ultrafiltration assay (Malmström et al. 2017).
2.3 Parathyroid hormone
PTH is secreted by the parathyroid glands and metabolized in the liver and kidney. There
are several circulating fragments of PTH: Intact PTH, N-terminal, 1-34 aminoacid
polypeptide, mid-molecule, and C-terminal peptide. Intact PTH and N-terminal PTH are
the biologically active forms (Potts et al.  2005).  PTH  has  an  important  role  in  the
regulation of calcium homeostasis in bone, kidney and the intestine. In bone PTH
mobilizes calcium from the skeleton by activating osteoclasts and increases calcium
absorption from the intestine. In the proximal renal tube of kidney, PTH activates the
hydroxylation of 25(OH)D to 1,25(OH)D, which leads to an increase in the intestinal
calcium absorption (Holick 2005). PTH also increases calcium reabsorption from the
thick ascending limb of nephrons and facilitates the secretion of phosphorus through the
kidneys. Calcium sensing receptor of the parathyroid glands detects when serum calcium
concentration is low and stimulates PTH release or suppresses PTH release in response
to high serum calcium. The calcium-sensing receptor is also expressed in several other
tissues including renal tubular cells, where it regulates calcium reabsorption, and bone
tissue and intestinal cells.
It is well established that PTH and 25(OH)D concentrations are inversely correlated and
that PTH increases when 25(OH)D concentrations are below a certain value.  PTH has
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been shown to decrease when vitamin D-insufficient subjects are given vitamin D
supplementation (Sai et al. 2011). High serum PTH concentrations can be caused by low
dietary calcium, skeletal muscle wasting, primary or secondary hyperthyroidism, chronic
kidney disease or inadequate vitamin D.  Chronically elevated serum PTH
concentrations impact bone density negatively by increasing osteoclast activity and the
urinary excretion of phosphorus (Åkerström et al. 2005).
2.4 Vitamin D binding protein
DBP has been known as a group-specific component (GC) since 1959 (Hirschfeld et al.
1960). In 1975 it was identified by Daiger et al. (1975) as the vitamin-D-binding protein
of human plasma. DBP has been found in several mammalian species and also in fish. It
may  be  present  in  all  vertebrates  as  a  vitamin  D  carrier  protein  (Daiger et al. 1975,
Constans et al. 1985, Constans et al.  1987).  DBP  is  a  polymorphic  protein  with  a
molecular  weight  of  52-59  kDa.  Its  structure  resembles  that  of  albumin  and  the  Į-
fetoprotein gene family (Speeckaert et al.  2006). DBP is composed of three domains of
a similar structure with a C-terminal truncation of the third repeat. The amino acid
sequence is composed of 458 amino acids (Cooke et al. 1985, Cooke et al. 1991, Braun
et al. 1993). The first domain between residues 35 and 49 has a Į-helical structure and it
binds vitamin D3 ligands. An actin binding domain is located between residues 373 and
403 (White et al. 2000). The vitamin D binding site is composed of hydrophobic residues
of helices 1e6 (amino acids 35e49). The binding site is located at the surface of DBP,
whereas the vitamin D binding site of the vitamin D receptor is a closed pocket in the
inner structure of the receptor (Verboven et al. 2002). The DBP structure is shown in
Figure 2.
DBP transports 25(OH)D from the liver to the kidneys. In kidneys and other organs,
25(OH)D is converted into 1,25(OH)D.  Approximately 85-90% of the circulating
25(OH)D and 85% of the 1,25(OH)2D  is  bound  to  DBP  (Bikle et al. 1986).
Chylomicrons  can  also  bind  small  amounts  of  vitamin  D  (Haddad  1995).  DBP  is
principally expressed in hepatocytes and in smaller amounts in the kidney. It delivers
vitamin D into cells by megalin-mediated endocytosis. In addition to serum, DBP is
localized in several body fluids such as urine, breast milk, ascitic fluid, cerebrospinal
fluid, saliva and seminal fluid and organs (brain, heart, lungs, kidneys, placenta, spleen,
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testes and uterus). In previous studies, DBP concentrations have been shown to be low
after liver diseases (Bikle 1985, Bikle 1986), nephrotic syndrome, and malnutrition. In
addition, pregnancy and oestrogen treatment elevate DBP concentrations (Bouillon et al.
1981, Hagenfeldt et al. 1991, Rejnmark et al. 2006). The explanation for lower
concentrations is probably reduced synthesis or increased loss of the protein (Speeckaert
et al.  2014). DBP concentrations are also shown to vary by the degree of insulin
resistance (Ashraf et al. 2014, Yousefzadeh et al. 2014). Season, vitamin D sterols, or
other  calciotrophic  hormones  (such  as  calcitonin  or  PTH)  do  not  influence  DBP
concentrations (Speeckaert et al. 2006).
A
Figure 2 A three-dimensional representation of DBP.  Surface representation (A) is showing the
three domains in different colors (blue: domain I; purple: domain II; green: domain III) and the
25(OH)D shown in yellow stick model. Į-helical structure is shown in figure 2 B and the common
polymorphism sites (residues 416 and 420) are shown in pink. Figure is modified from protein
data bank (PDB) structure 1J78 (Verboven et al. 2002).
B
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2.4.1 Functions of DBP
The main function of DBP is to bind and transport vitamin D and its metabolites (Daiger
et al. 1975). Each DBP-vitamin D metabolite complex has its own affinity constant.
25(OH)D binds DBP with a  high affinity (Ka= 5×10í8 M), whereas 1,25(OH)D binds
DBP with a lower affinity (Ka = 4×10í7 M) (Arnaud & Constans 1993, White et al. 2000).
DBP has a high plasma concentration (0.32–0.46 g/L) and a short half-life (2.5–3 days)
compared with 25(OH)D (5×10í8 M) and 1-2 months, respectively). Less than 5 % of
DBP binding sites are occupied with vitamin D metabolites. The large molar excess of
DBP in the circulation may protect against vitamin D intoxication by acting as a buffer
when vitamin D concentrations rise or work as a circulating pool of 25(OH)D (Cooke et
al. 1989, White et al. 2000).  The functions of DBP are described in Figure 3.
Figure 3. The free hormone hypothesis and the role of DBP-MAF in bone metabolism. Vitamin
D metabolites (blue circles) are transported by DBP in the circulation and a small amount is also
bound to albumin (bioavailable 25(OH)D) and lipoproteins. Free 25(OH)D and 1,25(OH)D can
cross the cell membrane freely by diffusion and interact with the VDR. In many tissues e.g.  the
kidney, parathyroid and placenta, 25(OH)D and 1,25(OH)D are bound to DBP and enter the cells
by endocytosis through the megalin/cubilin receptor. Modified from Delanghe et al. (2015) and
Bikle et al. (2017).
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2.4.2 Association of DBP with skeletal outcomes
Lower  BMD is  associated  with  vitamin  D  insufficiency.  However,  the  links  between
DBP and bone biology are not fully understood. The importance of DBP for the skeletal
system has been confirmed by disrupting the megalin gene in mice, resulting in an
elevated urinary excretion of DBP, bone deformation and decreased bone density (van
Hoof 2001). One mechanism for the effect of DBP on bone is through binding and
transportation of vitamin D metabolites. Another mechanism may be acting through GC-
macrophage activating factor (GC-MAF) (Yamamoto et al. 1993). GC-MAF is formed
when DBP is deglycosylated by ȕ-galactosidase and sialidase at the non-sterol binding
domain, which involves the osteoclast activating domain (Haddad 1995, White et al.
2000). Several in vitro studies in mouse/rat peritoneal nonadherent cells have discovered
that DBP is involved in macrophage activation. Furthermore, GC-MAF has been
proposed to be a possible activator of osteoclasts. Osteopetrotic rats treated with GC-
MAF showed a reduction in BMD and skeletal defects. In addition, osteopetrotic patients
appeared to lack the ability to form GC-MAF (Yamamoto et al. 1994, Schneider et al.
1995, 2003). GC-MAF has also been suggested to activate osteoclasts by a cellular
feedback mechanism that downregulates osteoclast activity when extracellular Ca
concentrations rise (Yamamoto et al. 1996). GC-MAF can also influence calcium
sensing of osteoclasts and thus stimulate bone resorption. The disruption of DBP
receptor coding gene in mice resulted in elevated excretion of DBP in urine as well as
deformation of bone and decreased bone density (van Hoof 2001).
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2.4.3 Other roles of DBP
In addition to transportation of vitamin D and regulation the concentrations of free
25(OH)D available for utilization, DBP has also several other roles.  Actin binds DBP
with  a  high  affinity  and  DBP  has  been  suggested  to  be  part  of  extracellular  acting
scavenging system. DBP can act  as  an extracellular  scavenger  for  actin released from
necrotic cells.  DBP binds fatty acids, but compared to albumin the binding capacity is
much weaker and there is a difference between them in the type of fatty acids they bind.
Thus DBP has only accompanying role in fatty acid transportation. Poly-unsaturated
fatty acids (arachidonic or linoleic acid) compete with vitamin D metabolites 25(OH)D
and  1,25(OH)D  for  DBP  binding.   DBP  has  also  been  proposed  to  have  a  role  in
leukocyte C5a-mediated chemotaxis (Cleve 1988, Haddad 1995, Gomme et al.  2004,
Speeckaert et al.  2006, Delanghe et al. 2015).
2.4.4 Measuring DBP
The specific method for measuring DBP has been under debate. DBP can be measured
with ELISA-assay using monoclonal or polyclonal antibodies. There has been discussion
about the suitability of measuring polymorphic DBP in groups of different skin colors
and genotypes with a monoclonal method. The monoclonal assay may bind differently
to DBP isoforms leading to underestimated concentrations. The underestimation occurs
particularly in individuals with homozygous GC1F variant (Bikle et al. 2017). This
genotype is more common in dark skinned individuals. In contrast to the monoclonal
ELISA-assay, the polyclonal method is not subject to bias (Bouiollon et al. 2014,
Denburg et al. 2016). A novel LC-MS/MS is also available for measuring DBP
concentrations.
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2.4.5 GC gene
DBP polymorphism has been established in both humans and primates (Constans et al.
1987). The human GC gene coding the DBP is localized on the long arm of chromosome
4 (4q12–q13). It over 35 kb long and contains 13 exons and 12 introns. The GC gene is
a  member  of  a  multigene  cluster.   Albumin,  Į-fetoprotein,  and  Į-albumin/afamin  are
other members of this cluster. All of these genes are primarily expressed in the liver
(Speeckaert et al. 2006). The GC gene has over 240 different variants (76 synonymous,
155 missense and 11 loss of function). The GC gene has two well-known missense
variations in exon 11: a Gௗ!ௗA substitution at codon 416 (E416D), which leads to a
glutamic acid to aspartic acid change, and a Cௗ!ௗA substitution at codon 420 (T420K),
which results in a threonine to lysine amino acid change (Braun et al. 1993) (Table 1).
Haplotypes of these nucleotide changes form protein isoforms GC1S, GC2, and GC1F.
Each GC gene variant has different combinations of two single-nucleotide
polymorphisms (rs4588 and rs7041) resulting in two amino acid substitutions and
differing glycosylation patterns. The two gene variants, rs4588 and rs7041, in general
combine to form six diplotypes: GC1S/1S, GC1S/2, GC1F/1F, GC1F/2, GC1F/1S, and
GC2/2 (Arnaud & Constans 1993). The structure of GC gene is shown in Figure 4 and
the SNPs associated with vitamin D metabolism are indicated in the picture.
Table 1. Alleles of GC SNPs rs7041 and rs4588 and the resulting protein composition.
Variant Alleles Protein composition at 416 and 420
GC1F T/C Aspartic acid/Threonine
GC1S G/C Glutamic acid/Threonine
GC2 T/A Aspartic acid/Lysine
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Polymorphisms in GC gene associated with 25(OH)D concentrations
The genetic polymorphisms in the two common SNPs (rs4588 and rs7041) of DBP have
repeatedly been associated with 25(OH)D concentrations (Table 2). The protein
isoforms differ in their binding affinity and capacity for carrying vitamin D metabolites.
They also influence the plasma concentration of 25(OH)D and 1,25(OH)2D. The
association of these SNP’s with vitamin D concentrations has been found in several
genome-wide association studies (GWASs) (Ahn et al. 2010, Wang et al.  2010, Sapkota
et al. 2016, Jiang et al. 2018) and many candidate gene studies indicating that this
polymorphism  has  the  greatest  impact  on  25(OH)D  concentrations  of  all  vitamin  D
related polymorphisms.
Beside the two common SNPs, also other polymorphisms in the GC gene have been
associated with 25(OH)D concentrations.  Two GWASs in European subjects (Ahn et
al. 2010, Wang et al.  2010) and two studies in Chinese subjects (Lu et al. 2012, Zhang
et al. 2013) reported SNP rs2282679, to have an association with vitamin D deficiency.
SNP rs1155563 is a GC gene variant that has been reported to be related to serum
25(OH)D concentration in several studies (Ahn et al. 2009, Lu et al. 2012, Hibler et al.
2014), and it has a high linkage disequilibrium (LD) with SNP rs4588. Two SNPs
(rs16846876 and rs222020) were identified that are not in LD with rs4588 and rs7041
(Bu et al. 2010, Hibler et al. 2012). SNP rs2298849, located in the first intron, has been
linked to serum 25(OH)D concentrations in an African American population (Signorello
et al. 2011) and a population of Chinese post-menopausal women (Xu et al. 2014). Six
SNPs in the GC gene (rs4588, rs16846876, rs2282679, rs12512631, rs17467825, and
rs842999) were significantly associated with 25(OH)D levels in Danish populations. Of
these, GC SNPs rs4588 and rs842999 were in strong LD. GC rs4588 and rs842999
without risk alleles had higher 25(OH)D concentrations than carriers of risk alleles
(Nissen et al. 2014).
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Table 2. Summary of reviewed studies on the association of GC gene SNP’s with 25(OH)D
concentrations
Reference Subjects GC SNP’s Main findings
Ahn et al.
2010
European ancestry from
five cohorts, N=4501
GWAS - SNPs rs2282679, rs7041 and
rs1155563 were associated with
25(OH)D concentrations.
-A heterozygote of SNP rs2282679 was
at higher risk of vitamin D deficiency.
Wang et al.
2010
European ancestry from
15 cohorts,  N=33996
GWAS - SNP rs2282679 associated with
25(OH)D concentrations.
-Participants with a genotype score in
the highest quartile were at increased
risk of having 25(OH)D < 75 nmol/L or
< 50 nmol/L compared with the ones in
the lowest quartile.
Sapkota et
al. 2016
A Punjabi Sikh diabetic
cohort, N=3538
GWAS -Allele G of SNP rs2282679 was
negatively associated with 25(OH)D
concentration.
Jiang et al.
2018
Subjects of European
descent, N=79 366
Meta-
GWAS
- Common genetic variants regulated the
25(OH)D concentrations.
Ganz et al.
2018
Healthy third-trimester
pregnant women, N=26
lactating women, N=28
non-pregnant women,
N= 21
rs7041 - GC SNP rs7041 altered circulating
vitamin D metabolites in all the study
groups.
- SNP rs7041 T allele associated with a
different metabolic response to
pregnancy and placental vitamin D
metabolism.
Petersen et
al. 2017
Healthy 8–11-year-old
Danish children, N=642
rs4588
rs7041
rs2282679
rs842999
- rs4588 and rs7041 associated with
lower 25(OH)D concentrations in all
seasons.
Moon et al.
2017
White women
(351 placebo, 331
cholecalciferol) double-
blind, randomized,
placebo-controlled trial
of vitamin D
supplementation in
pregnancy.
rs2282679 - In the vitamin D supplement group, the
common A allele of rs2282679 was
associated with higher 25(OH)D
concentration at 34 week pregnant
women.
Zhang et al.
2013
Chinese subjects,
N=2897.
rs2282679 - rs4588 and rs2282679 associated with
25(OH)D concentrations
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Table 2 continues
Reference Subjects GC SNP’s Main findings
Li et al.
2017
A cross-sectional
study of elderly post-
menopausal Chinese
women, N=967.
rs4588
rs7041
- SNP rs7041, but not rs4588, was associated
with DBP concentration.
- DBP correlated positively with 25(OH)D but
negatively with bioavailable 25(OH)D.
- Bioavailable 25(OH)D may be a more reliable
biomarker in bone health.
Perna et al.
2013
Cohort study of 2160
women and 1581 men,
aged 50-74 years.
rs4588
rs2282679
rs1155563
- Inverse association between rare alleles of
SNPs rs4588, rs2282679 and rs1155563 and
vitamin D concentrations. Association was
stronger in summer months.
Nissen et al.
2014
Healthy Danish
children and adults,
N=758
rs4588,
rs222020
rs842999
rs2882679
rs2298849
rs12512631
rs16846876
rs17467825
- SNPs rs4588, rs842999, rs2282679,
rs12512631, rs16846876 and rs17467825 were
associated with 25(OH)D concentrations in
children, adults and, all combined.
- rs4588 and rs842999 had significantly higher
25(OH)D concentration than carriers of all risk
alleles.
Lu et al.
2012
Chinese Hans,
N=3210
rs4588 rs7041
rs2282679
- GC SNPs rs4588, rs7041, rs2282679 and
rs1155563 were all associated with lower
25(OH)D.
- GC haplotypes that contained all risk-alleles
(TACC) was significantly associated with lower
plasma 25(OH)D.
- Haplotype containing the risk alleles of rs4588
and rs2282679 (TATC) were associated with
lower 25(OH)D.
Hibler et al.
2014
Ursodeoxycholic acid
(UDCA) clinical trial
subjects,  N= 403
7041
4588
- Lower 25(OH)D concentration in clinical trial
participants with 1F/2, 1S/2, or 2/2 compared
with 1S/1S.
- Cellular data revealed that 25(OH)D uptake
varied less by GC isotype only at the higher
concentration tested while 1,25(OH)D uptake
differed markedly by GC isotype across
concentrations and assays.
Hibler 2012 Participants from the
Ursodeoxycholic Acid
(UDCA) and Wheat
Bran Fiber (WBF)
trials N=404 subjects
rs7041
rs222035
rs842999
rs1155563
rs12512631
rs16846876
rs1746825
- Significant associations between GC SNPs
rs7041, rs222035, rs842999, rs1155563,
rs12512631, rs16846876, and rs1746825 and
circulating 25(OH)D
Bu et al.
2010
Caucasian subjects,
N=156.
9 genes in
vitamin D
metabolic
pathways, 49
SNPs
- GC genotype may contribute to the variation of
25(OH)D in healthy populations.
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Polymorphisms in GC gene associated with bone
GC polymorphisms have been linked with alterations in bone density in several populations.
One of the mechanisms by which DBP may alter bone health involves regulating vitamin D
bioavailability. Additionally, DBP may have independent roles in macrophage and
osteoclast activation. The common GC SNP’s are situated in exon 11(domain III) which is
also an area responsible for nonsterol activities of DBP together with domain II and
furthermore of the macrophage/osteoclast activation of DBP (Fang et al. 2009). Several
studies have reported an association of GC polymorphism with bone density and fracture
risk (Table 3).  The results  are  inconsistent  between the studies,  and it  is  unclear  whether
there  is  an  interaction  of  DBP  or GC genetic polymorphism and circulating 25(OH)D
concentrations and bone mass.
Table 3. Summary of reviewed studies on the association of DBP SNPs with bone traits
Reference Subjects SNP Method Main Finding
Ezura et al.
2003
Adult Japanese
women, N=384
Multiple
SNPs of
the GC
gene
DXA -Multiple GC SNPs might
contribute to increased risk
of osteoporosis.
Lauridsen
et al. 2004
Danish (white)
menopausal
women, N=595
rs4588,
7041
Bone density and
bone mineral
content were
measured with
DXA, history of
fractures was
collected
-DBP phenotype associated
with fracture risk.
-No association of DBP
phenotype with bone
mineral content or BMD.
-DBP concentration
correlated with fractures.
Fang et al.
2009
over 55 years old
Caucasian men,
N=3105 and
women, N=4878
rs7041
rs4588
Fracture risk - GC haplotypes associated
with 25(OH)D
concentrations.
- GC gene had an effect on
fracture risk, especially at
low dietary Ca intake or in
combination with an
osteoporosis-risk allele of
the VDR gene.
Xu et al.
2010
Caucasian men
and women from
United States,
N=1873
12  SNPs
of the GC
gene
DXA - GC SNPs rs222029 and
rs222020 were associated
with bone compression
strength index in men.
Giroux et
al. 2010
N=673 18–35-
year-old women
12 SNPs
of the GC
gene
- No association of GC
genotype with BMD.
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Geographical distribution of the GC alleles
The GC SNPs rs4588 and rs7041 have a geographical distribution over three common
alleles. Caucasian populations have a lower frequency of the GC1F allele and a higher
frequency (50-60%) of the GC1S allele. The GC1F allele frequency is higher among black
Americans and black Africans. The GC1F and GC1S allele frequencies have a geographical
cline from Southeast Asia, through Europe and the Middle East, to Africa. In all populations,
there is less of the GC2-allele than the GC1 allele, although Europeans do have a markedly
higher GC2 allele frequency than do other ancestral groups. The variation in the GC allele
frequencies may be correlated with skin pigmentation and intensity of sun light exposure.
Dark-skinned  and  keratinized  skin  types  have  a  lower  rate  of  UV light  penetration  and  a
higher risk of rickets. The higher frequency of GC1F in dark- skinned persons relative to the
white-skinned population may be due to its greater affinity for and more efficient transport
of vitamin D metabolites (Malik et al. 2013). Several studies in black and white Americans
and many other large genetic studies in numerous populations worldwide (Europeans, West
Africans, Arabs, Danes, Korean, and Chinese) have shown associations between the GC1F
and GC2 variants and lower concentrations of serum 25(OH)D (Constans et al. 1985).
2.5 Vitamin D, DBP, and obesity
Recent studies have suggested that there may be a connection between vitamin D deficiency
and cardiometabolic diseases, such as obesity, impaired glucose tolerance, and diabetes
mellitus type 2, arterial hypertension, and atherogenic dyslipidemia. Although the
mechanisms are still unclear, vitamin D deficiency is associated with a greater risk of these
conditions (Forman et al. 2008, Heaney et al. 2008, Bikle et al. 2009, Holick et al. 2011,
Vanlint 2013, Ke et al. 2015, Wang et al. 2016, Gul et al. 2017, Lips et al. 2017).
Alterations in the vitamin D endocrine system have been shown to be associated with
obesity. Increased adiposity is reported to be positively associated with serum PTH
concentrations and inversely associated with serum 25(OH)D concentrations (Wortsman et
al. 2000, Snijder et al. 2005, Shirazi et al. 2013). One reason could be the increased
sequestration  of  25(OH)D  in  excess  subcutaneous  fat,  leading  to  a  decrease  in  the
bioavailability of vitamin D for calcium absorption (Drincic et al. 2012). The decreased
availability  of  serum  25(OH)D  causes  an  increase  in  PTH  secretion  to  maintain  serum
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calcium concentrations. Other reasons suggested for lower vitamin D status in obese subjects
could be low dietary intake of vitamin D and less sunlight exposure due to limited mobility
or clothing habits among the obese compared with normal-weight individuals (Compston et
al. 1981, Hypponen&Power 2007). Although the circulating 25(OH)D may be lower in
obese individuals than in normal-weight peers, concentrations of vitamin D might not be
lower and obese subjects may have greater vitamin D stores than normal-weight individuals.
This in combination with low intake of vitamin D may lead to lower serum concentrations.
However, overweight may also be the consequence of poor vitamin D status.
Many studies have investigated the relationship between 25(OH)D and insulin
concentrations (Mc Gill et al. 2008, Pinelli et al. 2010). Vitamin D receptors and 1-Į-
hydroxylase have been found in pancreatic ß-cells, and this finding has led to studies on the
possible effects of calcitriol on regulation of insulin production. Hence, vitamin D may have
a role in controlling the function of ß-cells (Bland et al. 2004).
DBP has been shown to be lower in obese adolescents than in normal-weight subjects, and
DBP and 25(OH)D correlated positively.  There was also an inverse relationship between
insulin and DBP concentrations in obese subjects. The authors suggested that insulin
suppresses the production of DBP (Ashraf et al. 2014). In another study, obese women had
higher DBP concentrations and lower free 25(OH)D than normal-weight women. The obese
women were more likely to have 25(OH)D concentrations that could be considered
suboptimal (Karlsson et al. 2014).
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2.6 Bone
2.6.1 Bone structure
Bone comprises of cortical bone and trabecular bone.  Up to 66% and 75% of lumbar and
thoracic  vertebrae  is  trabecular  bone,  respectively,  whereas  at  distal  radius  only  5%  is
trabecular. The femoral neck is 75% cortical bone. Cortical and trabecular bone differ in
their response to diseases, medication, hormonal changes, muscle-loading and impact-
loading physical activity. Cortical bone is dense and solid tissue that surrounds the marrow
space and trabecular bone. Cortical bone is located at the periosteal surfaces and in the
middle of long bones and is responsible for the strength of the bone, provides resistance
against bending and prevents bone from fracturing. Trabecular bone is a porous structure
and consists of trabecular plates and rods, which strengthen the bone.  Because trabecular
bone  is  less  dense,  it  has  more  surface  area  per  unit  volume  than  cortical  bone  and  it  is
therefore flexible but weaker than cortical bone.  Trabecular bone is located at the endosteal
surfaces and at the end of long bones. Trabecular bone is metabolically more active and has
a much higher remodelling rate.
Cortical bone is essential for the support of the body and its organs. Cortical bone also stores
and releases chemical elements, most importantly calcium. Cortical bone consists of several
microscopic columns (osteons), which are the functional units. Osteons have multiple layers
of osteoblasts and osteocytes around Haversian canal. The osteons are connected together
by Volkmann’s canals. Nerves and blood vessels go through Haversian canals. Cortical bone
is divided into periosteal surface and endosteal surface.  Periosteum surrounds the outer
cortical surface of the cortical bone and endosteum covers the inner surface and separates
cortical bone and trabecular bone. Periosteum contains blood vessels, nerve fibres,
osteoblasts, and osteoclasts.  It protects and nourishes the bone and takes part in bone
formation. Periosteum has an important role in appositional growth and fracture repair (Kini
& Nandeesh 2012, Florensio-Silva et al. 2015).
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2.6.2 Bone remodelling
Bone undergoes continuous remodelling. Remodelling helps bone to adapt to changes and
to remove old bone and replace it with new stronger bone. Osteoclasts remove old bone by
resorption and osteoblasts form new bone. Also the bone lining cells and osteocytes take
part in bone remodelling. In growing bones, there is less remodelling and more modelling.
During growth new osteons are formed and more bone is formed than resorbed. Modelling
takes place mainly at the epiphysis of long bones leading to changes in shape and size of
bone (Rauch et al. 2001, Bikle 2012).  During ageing, bones expand in response to periosteal
apposition of new bone and endosteal resorption of old bone. Bone modelling may increase
due to hypoparathyroidism, renal osteodystrophy or treatment with anabolic agents (Ubara
et al. 2003, Ubara et al. 2005, Lindsay et al. 2006).
2.6.3 Skeletal life span

Childhood and adolescence
Childhood and adolescence are characterized by longitudinal growth of bones as well as in
changes in skeletal size and shape. Bone modelling begins already during foetal growth.
Bone mass increases steadily during childhood and markedly during adolescence.  By the
end of adolescence, most of the adult skeleton is formed. Skeletal growth involves deposition
and resorption of bone where bones expand (periosteal apposition of cortical bone) and
lengthen (endochondral ossification) (Parfitt 1994). By the end of the second decade of life
(19 years), epiphyseal fusion occurs (Heaney et al. 2000). Increases in trabecular bone in
spine and long bones take place between sexual maturation stages (i.e. Tanner stages) III
and IV.  The density of cortical bone is lower among children and adolescents than among
adults.  Especially in boys, there can be occasional changes in cortical bone where the
porosity of the bone increases. Boys have greater bone mineral content (BMC) and areal
BMD than girls and the differences become stronger in puberty (Weaver et al. 2016). BMD
increases during growth due to rise in bone size. However, volumetric bone density increases
only modestly (Seeman 2002).
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Adulthood
The adult skeleton is quite stable between the ages of 20 and 40 years and bone modelling
is less frequent than remodeling in adults.   Lifestyle factors, such as nutrition, smoking,
alcohol use, and physical activity and, certain medications and diseases may have an impact
on bone (Kobayashi et al. 2003).
In women, there is a reduction of bone at menopause due to a decrease in oestrogen
production. Women are estimated to lose 30-50 % of their bone mass by the age of 70 years.
In men, the bone loss is not so rapid. They have a steady continuous decline in bone mass in
the fifth and sixth decade of life (40-60 years). Women are more susceptible to osteoporosis
than men, due to their lower peak bone mass and greater bone loss.
2.6.4 Osteopenia and osteoporosis
Osteoporosis is characterized by lowered BMD due to accelerated bone turnover. In this
condition, more bone is resorbed than formed. These changes lead to bone fragility and
predisposition to fractures. In osteoporosis the amount of bone is decreased and the structure
of trabecular bone is impaired. In addition, cortical bone becomes more porous and thinner,
making the bone weaker and more prone to fracture (Karaguzel & Holick 2010, Mirza et al.
2015). Bone loss occurs in all humans due to hormonal changes. The primary reason for both
sexes is estrogen deficiency. Osteopenia is a precursor phase to osteoporosis but it does not
always develop into osteoporosis. The difference between osteopenia and osteoporosis is
based on BMD. Both men and women have a risk of having osteopenia/osteoporosis, but
menopausal women are at the highest risk. Osteoporosis is divided into primary and
secondary osteoporosis. Osteoporosis is classified as primary, when it occurs in
postmenopausal women and men and is age-related and there is no underlying disease.
Secondary osteoporosis is a condition that occurs when there is an underlying disease or
medication (Mirza et al. 2015).
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T-score and Z-score
T-score is often used when bone density measurements are interpreted. T-score is the number
of standard deviations below or above the average healthy adult bone mass. T-scores depend
on the reference group used (e.g. Caucasian women or Hispanic men).  Z-score is the number
of standard deviations below the average of the same-age and gender person. There are also
different Z-scores depending on the group used as a reference. T-score and Z-score can be
calculated for each bone parameter. In osteopenia BMD T-score is between í1.0 and í2.5.
In  osteoporosis  the  T  score  is  lower  than  í2.5.  The  WHO  definition  is  based  on  BMD
measurement with DXA at the spine, hip, or forearm (Kanis et al. 1994).
2.6.5 Biochemical markers of bone metabolism
Bone formation and resorption rates can be detected with several biomarkers from serum or
urine. The markers are often bone proteins, collagen fragments, peptides, or enzymes.
Alkaline phosphatase (ALP) is important for bone mineralization and both total ALP and
bone specific ALP (BALP) are used as bone formation markers.  Other bone formation
markers include bone matrix protein osteocalcin and propeptides of collagen I called
carboxy-terminal and amino-terminal propeptides of type I procollagen (PICP and PINP).
Markers of bone resorption, in turn, include, collagen degradation products: telopeptides of
type I collagen: Carboxy-terminal Crosslinked Telopeptide of type I collagen (CTX-I) and
CTX-matrix metalloproteinases and N-terminal telopeptide I (NTX-I), Hydroxyproline,
Deoxypyridinoline, Pyridinoline and Hydroxylysine. Non-collagenous proteins include
Bone sialoprotein (ostepontin), and osteoclastic enzymes:  Cathepsin K and Tartrate-
resistant acid phosphatase.  Bone turnover regulators consist of Receptor activator of nuclear
factor kappa-B ligand (RANKL), Osteoprotegerin (OPG), Dickkopf related protein 1, and
Sclerostin (Kuo & Chen 2017).
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Osteocalcin
Osteocalcin (bone gamma-carboxyglutamic acid-containing protein) is a small protein
synthesized by mature osteoblasts, odontoblasts, and hypertrophic chondrocytes. The
synthesis of osteocalcin is stimulated by 1,25(OH)D. Most of the osteocalcin is situated in
bone. Carboxylation of glutamic acid residues leads to a conformational change in protein.
The change in protein structure allows the binding of osteocalcin with hydroxyapatite and
mineralization in the bone matrix (Hlaing et al. 2014).  Osteocalcin is  also secreted in the
circulation. The protein has an important role in metabolic regulation, bone mineralization
and calcium homeostasis (Lee et al. 2007).
Serum osteocalcin has been used as a marker of bone formation rate in osteoporosis.
Postmenopausal women with osteoporosis or osteopenia have been shown to differ
significantly in their osteocalcin concentrations from non-osteoporotic women.
Consequently, osteocalcin may be useful for determining osteoporosis in elderly persons and
especially in women (Singh et al. 2015).
Procollagen type I N-terminal propeptide (PINP)
PINP is synthesized by fibroblasts and osteoblasts and is an indicator of type I collagen
deposition in bone matrix.  Procollagen type I has N-terminal and C-terminal extensions,
which are removed by specific proteases when it is converted to collagen. PINP is released
during formation of type I collagen into the intracellular space. PINP concentrations can be
measured by ELISA-assay or radioimmunoassay using PINP antibodies. PINP has been
demonstrated to be a sensitive biomarker to measure bone formation rate in osteoporosis
(Kuo & Chen 2017).
Carboxy-terminal crosslinked telopeptide of type I collagen
Telopeptides of type I collagen are bone resorption biomarkers that include collagen type I
carboxy-terminal crosslinked (CTX-I) and amino-terminal crosslinked (NTX-I)
telopeptides. They are both released during collagen degradation. NTX  and  CTX  are
excreted in urine and can also be measured from serum.  The concentrations have circadian
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variation and therefore the timing of the sample collection is important.  CTX and NTX can
be measured with ELISA, RIA and electrochemoluminescence assays. The advantage of
serum markers  compared  to  urine  markers  is  that  the  results  do  not  need  correction  with
creatinine (Hlaing et al. 2014, Kuo & Chen 2017).
2.6.6 Factors affecting bone
Vitamin D
Vitamin D deficiency is one factor that predisposes bone to osteoporosis. Vitamin D
deficiency causes a decrease in calcium absorption, which is compensated by an increase in
PTH, stimulating the conversion of 25(OH)D into 1,25(OH)2D. In vitamin D deficiency,
calcium absorption decreases leading to increase in PTH. Excessive secretion of PTH by the
parathyroid glands called secondary hyperparathyroidism, in response to low blood calcium
concentrations, increases bone turnover, leading to bone loss (Lips 2001, 2006). Severe
vitamin D deficiency can result in rickets in children or osteomalacia in adults.  Studies have
found a positive association between 25(OH)D concentrations and BMD (Outila 2001,
Bischoff-Ferrari 2004). There is convincing evidence that supplementation with vitamin D
at a dose of 10–20 μg/d combined with calcium, reduces the risk of total fracture and hip
fracture. The effect is more pronounced in institutionalized elderly persons, and
supplementation with vitamin D alone has not shown a significant impact (Lamberg-Allardt
et al. 2013).
Other determinants of bone health
Lifestyle factors, such as nutrition and physical activity, are important for bone mass accrual
during growth and for maintaining bone in adulthood. The role of calcium and vitamin D in
improving BMD and reducing fracture risk has been established. Persistently low 25(OH)D
may result in prolonged elevation of PTH, leading to an increase in bone resorption. The
optimal  concentration  of  25(OH)D  required  for  optimum  peak  bone  mass  remains  to  be
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elucidated. Adequate protein intake is also important for bone health. Excessive intake of
alcohol has adverse effects on bone-forming cells as well as on the hormone that regulates
calcium metabolism. Also poor nutritional status (calcium, protein, and vitamin D
deficiency) due to excessive alcohol consumption can cause secondary osteoporosis (Kanis
et al.  2005). People with a past history of smoking and current smokers are at higher risk of
having osteoporosis than non-smokers (Kanis &Johnell 2005). Eating disorders, such as
anorexia nervosa and bulimia, also affect bone negatively. Oestrogen deficiency in post-
menopausal women accelerates bone loss. Certain medications such as corticosteroids can
affect bone negatively. Osteoporosis induced by glucocorticoids is primary cause of
secondary osteoporosis (Mitra 2011). Genetic factors play an important role in the
pathogenesis of osteoporosis. It has been suggested that up to 50-85% of peak bone mass
and some geometrical properties can be determined genetically (Ralston 2006).
2.6.7 Bone assessment
Dual energy X-ray absorptiometry (DXA)
DXA measurements are used in accordance with a WHO guideline for the diagnosis of
osteoporosis and fracture risk in adults. DXA measures the attenuation of X-rays of two
different energies when passed through the body, and computes the BMC (in grams) and
areal BMD for a given region. The common measurement sites for DXA are hip and lumbar
spine. Also whole-body BMD measurement is used. The limitation of DXA is that it gives
only a two-dimensional image and cannot, therefore, separate cortical and trabecular bone,
or assess three-dimensional geometry and microarchitecture (Bouxsein 2008).
Peripheral quantitative computed tomography (pQCT)
Peripheral quantitative computed tomography (pQCT) is used for imaging bone as well as
fat and muscle tissues surrounding the bone. pQCT is used only for research purposes, not
in clinical practice. pQCT gives a three-dimensional image of the bone. Trabecular- and
cortical- and volumetric bone density (vBMD) as well as bone size and geometric properties,
e.g. total cross-sectional bone area, cortical bone area, periosteal and endosteal
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circumferences,  and cortical  thickness can be measured with pQCT from peripheral  sites.
The cross-sectional moment of inertia (CSMI) and other measures of bone strength, such as
the bone strength index (BSI), polar strength strain index (pSSI), and cortical strength index
(CSI), can then be calculated (Siu et al. 2003).
The benefits of pQCT compared with DXA are the very low radiation dose and the ability
to distinguish between trabecular and cortical bone. pQCT-measurement also takes into
account  the  size  of  the  bone,  and  therefore,  quantification  of  volumetric  BMD  is  more
reliable (Binkley et al. 2008).
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3 AIMS OF THE STUDY
The purpose of this thesis was to investigate the associations of DBP genetic polymorphism
with calcium homeostasis and BMD in children and adolescents as well as in middle-aged
individuals in Finland. Specific aims were to examine the metabolism of free vitamin D and
to determine whether obese individuals have altered vitamin D metabolism. The questions
seeking answers in Studies I-III were as follows:
Study I: Does genetic polymorphism of DBP have on effect on BMD and calcium
metabolism in Finnish children and adolescents in a cross-sectional setting?
Study II: Do total, free and bioavailable 25(OH)D, vitamin D binding protein, and PTH
concentrations relate to the genetic variation of the GC gene in Finnish middle-aged women
and men in a cross-sectional setting?
Study  III:  Do  obese  individuals  have  altered  vitamin  D  metabolism  and  whether  this  is
associated with BMD in a cross-sectional study of Finnish middle-aged women and men?
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4 SUBJECTS AND METHODS
4.1 Subjects and study design
4.1.1 Study in children and adolescents (I)
Study I combined subjects from two different cross-sectional studies (the Optiford-study and
the School-based study) in the capital region of Helsinki (60°N), southern Finland. The total
study population consisted of 233 children and adolescents, 160 girls (mean age 13±2.5
years) and 73 boys (mean age 12.6±2.7 years). Participants in the Optiford-study were girls
(N=50) aged 11-12 years and in the School-based study boys (N=73) aged 12.6±2.7 years,
and girls (N=110) aged 13±2.5 years. The original purpose of the Optiford-study was to
examine the efficacy of vitamin D-containing, dietary-supplement use in children and
adolescents and the School-based study investigated vitamin D status and its association
with vitamin D intake and bone health in children and adolescents. Recruitment in both
studies was conducted in primary schools and in the School-based study also in a secondary
school. School classes were randomly selected to the study. All participants were healthy
and used no medication known to affect calcium metabolism. Over 90% of the subjects were
Caucasian.  The Optiford-study was conducted between September 2001 and March 2002
and is described in detail in Viljakainen et al. (2006). The School-based study was conducted
during 2007-2008 and is described in detail in Pekkinen et al. (2012).
4.1.2. Cross-sectional study in middle-aged men and women (II-III)
The subjects in Studies II and III were 37- to 47-year-old Caucasian females and males from
the study “Dietary phosphorus and health outcomes (PHOMI)”, which is a cross-sectional
study of Caucasians living in the Helsinki area (60°N, southern Finland) who were derived
from the Population Register Centre. Recruitment and the study protocol are described in
detail in Itkonen et al. (2013).  The principal aim of the PHOMI-study was to examine
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dietary phosphorus intake and its impact on cardiovascular and bone health. The study aimed
to have 800 subjects (400 women, 400 men). The sample size was based on a statistical
power of 80% (Į= 0.05) to find a 4% difference (SD=0.050 g/cm3) in distal radius trabecular
density (TraD) between the highest and lowest phosphorus intake tertiles by analysis of
variance.  Initial dropout of 40% (based on 1200 participants) was taken into account.
Pregnancy was an initial exclusion criterion in the study.  Subjects visited the research unit
two times during spring 2010: on the first visit (January or March), fasting blood samples
and urine samples were collected and subjects were instructed to fill in a study questionnaire.
The total number of participants in blood sampling was 678. In the second phase i.e. pQCT
bone measurements, 653 subjects of these participated. Due to missing data (e.g.
background, blood sample, genotype, DBP concentration), the total number of subjects
included in Study II was 622 (421 women and 201 men). Morbidly obese subjects (BMI40),
chronically ill and participants with frequent use of sunbed (> 10 times during 2008–2010)
were excluded from the analysis.  In total, 606 subjects were included in the Study II
analysis. Also in Study III, morbidly obese subjects (BMI40), chronically ill and
participants with frequent use of sunbed (>10 times during 2008–2010) were excluded from
the analysis. In vitamin D, PTH and DBP analysis of Study III, the number of subjects was
548 (384 women and 164 men).
In Study III, subjects with a history of eating disorder, menopause (women who reported
their menstrual cycle had ended), or medication or illnesses affecting calcium or bone
metabolism were excluded from the pQCT-bone analysis resulting in 547 subjects (350
women and 197 men).
4.1.4 Ethics statement
All subjects in Studies I-III, and in Study I also the parents of the participants, gave their
written informed consent to the study procedures.  All of the studies were conducted in
accord with the Helsinki Declaration. The study protocol was approved by the Ethics
Committee of the Hospital District of Helsinki and Uusimaa.
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4.2 Methods
4.2.1 Background characteristics
Children and adolescents (Study I)
The subjects together with their parents completed a questionnaire on medical and fracture
history, medications, overall health, age at menarche, use of vitamin D and Ca supplements,
and details about their physical activity. A FFQ based on Outila et al. (2001) was used to
measure dietary intakes of vitamin D and Ca during the previous month. Necessary changes
were made to the FFQ to take into account changes in vitamin D-fortified products on the
market. An updated version of the FFQ was later validated (Itkonen et al. 2016).
Weight was transformed into height-adjusted values (percentages of the mean in a normal
population of the same sex and height), according to Finnish standards (Sorva 1990, Pere
2000). Pubertal development was scored as pre-, mid-, or postpubertal (School-based study)
by a pediatric endocrinologist (Outi Mäkitie) or according to Tanner stages I–V (Optiford-
study). The scoring was made based on questionnaire data and serum gonadotrophin and sex
steroid concentrations. The Tanner stages were then transformed into pre-, mid-, or
postpubertal  categories  to  acquire  a  united  scale  for  all  subjects.  Tanner  stages  I–II  were
considered as prepubertal, stages III and IV midpubertal and stage V as postpubertal.
Physical activity consisted of everyday activities (e.g. walking to school), activity at school,
and both guided and unguided leisure-time activities. Physical activity score was calculated
by summing a whole week’s different activities, as described in Pekkinen et al. (2012).
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Adults (Study II, III)
The subjects answered a questionnaire on medications and overall health, use of vitamin D
and Ca supplements, and details about their physical activity. A FFQ based on Outila et al.
(2001) was used to measure dietary intakes of vitamin D and Ca during the previous month
in  all  studies.  Necessary  changes  were  made  to  the  FFQ to  take  into  account  changes  in
vitamin  D-fortified  products  on  the  market.  An  updated  version  of  the  FFQ  was  later
validated (Itkonen et al. 2016).
In Studies II and III, both supervised and unsupervised exercise as well as functional exercise
were taken into account when physical activity was calculated in minutes per week. Sunshine
exposure was estimated from the number of holidays spent in sunny locations (exposure to
UV-irradiation) from November 2009 to January 2010 or from November 2009 to March
2010 depending on the month that blood was sampled. Amount of smoking was estimated
as pack years (number of cigarette packs per day x number of years smoking). Weight and
height were measured in light clothing and BMI was calculated as kg/m2. In Study III,
subjects were classified into BMI groups: normal-weight (18.5-24.9 kg/m2), overweight (25-
29.9 kg/m2), or obese (30-39.5 kg/m2) (WHO 2000).
4.2.2 Laboratory analyses
Blood samples and second void urine samples were collected at 8–10 am after an overnight
fast between November and March (School based study) or between September and March
(Optiford study). In the PHOMI study (Studies II and III), twelve-hour fasting blood
samples and second void urine samples were collected between 7:30 am and 9:15 am in
January or March 2010.  A summary of the laboratory measurements in Studies I-III is
provided in Table 4.
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Table 4. Summary of laboratory measurements in Studies I-III
DFVR; Danish Institute for Food and Veterinary Research, Søborg, Denmark, UCC; Department of Food
and Nutritional Sciences and Biosciences Institute, University College Cork, Ireland, UH; Department of
Food and Environmental Sciences, Division of Nutrition, University of Helsinki, Finland,
HUS; Central Laboratory of Helsinki University Central Hospital, Finland.
Study Method Location of
analysis
CV %
25(OH)D I HPLC (DEQAS) DFVR (Optiford)
HUS (School
based-study)
Optiford: 4.3, 6.3
School based
study:
Information not
available
II, III IDS enzyme immunoassay kit
(Immunodiagnostics Systems
Ltd., Boldon, UK)
UH 2.7 (inter)
3.2 (intra)
PTH I Commercial two-site
immunoluminometric method
UH (Optiford),
HUS (School
based-study)
8.0 (inter), <5.5
(intra) (II, III)
II, III Immunoluminesence-based
method (Immulite1000,
Siemens Healthcare
Diagnostics, NY, USA)
UH
Calcium I-III Photometric method with
Konelab20 automatic
analyzer  (Thermo Clinical
Labsystems, Espoo, Finland)
UH (Optiford),
HUS (School
based-study)
UH (II, III)
<4.6 (II, III)
Albumin II, III Photometric method with
Konelab20 automatic
analyzer
UH <4.6 (II, III)
DBP II, III ELISA-assay using
polyclonal antibodies
UH
Osteocalcin II, III Two-site immunoassay-
method based on monoclonal
antibodies
Department of
Cell Biology and
Anatomy, Institute
of Biomedicine,
University of
Turku
S-CTX II, III IDS-iSYS Multidiscipline
Automated Analyser
NordLab Oulu,
Department of
Clinical
Chemistry,
University of Oulu
intra<5.3,
inter<2.9
S-iPINP II, III IDS-iSYS Multidiscipline
Automated Analyser
U-Ca, UPi,
UCrea
I Standard methods UCC(Optiford)
HUS (School
based-study)
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4.2.3 Genotyping (I, II)

Genomic DNA was extracted from whole-blood samples with commercially available kits.
DNA extraction and genotyping methods are described in Table 5. In Study I, the rs4588
and rs7041 SNPs were genotyped. In Study II, SNPs covering the DBP gene region were
selected from the International HapMap Project database
(https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/).
The function “Download tag SNP data” was used and three polymorphisms were chosen:
rs4588, rs7041and rs705124. These polymorphisms represented the linkage disequilibrium
structure of a region. Preference was given to polymorphisms with high heterozygosity
levels and SNPs that are functional and have previously shown association in other studies.
Northern Europeans from Utah (CEU population) was used as a reference when selecting
these three SNPs.
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Table 5. DNA extraction and genotyping methods in Studies I-II
Study Method
DNA
extraction
method
I Optiford study:
Wizard® Genomic
DNA Purification kit,
(Promega,
Madison,WI, USA)
School based study:
Gentra Puregene Kit
(Qiagen GmgH
Hilden, Germany)
II Qiagen DNA Mini Kit
Genotyping I RT PCR Mx3000P,
(Stratagene, La Jolla,
CA)
Primers:
ƍGGCAAAGTCTGAGCGCTTGTTA3ƍ
and
ƍCAGACTGGCAGAGCGACTAAAAG3ƍ
Probes:
ƍNEP/TTGCCT GAG GCC ACA
CC/NEP-3ƍ
ƍMAR/TTGCCTGATGCCACACCC/MA
R-3ƍ,
ƍNEP/CCACACCCAAGGAACTGGC/NE
P-3ƍ and 5ƍMAR/CACACCCACGGAACT
GGC/MAR-3ƍ
II TaqMan chemistry, an
automatic sequence-
detection instrument
(ABI Prism 7900HT,
Applied Biosystems,
Foster City, CA, USA)
Probes (AllGloTM,
Allelogic Biosciences
Corporation, Hayward,
CA, USA).
Probes:
FAM dye label
VIC dye label
SNP Assay ID C___8278879_10
SNP Assay ID C___3133594_30
SNP Assay ID C___8278822_10
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4.2.4 Calculation of free and bioavailable 25(OH)D (II-III)
Calculation of free 25(OH)D in studies II and III was performed using the following equation
where [F] is concentration of free 25(OH)D and [T] is concentration of total 25(OH)D and
KALB and KDBP are the affinity constants for 25(OH)D with albumin and DBP and [ALB]
and [DBP] are the concentrations of albumin and DBP (Bikle et al. 1986):
[ࡲ]= (T)
(1 + KALB [ALB] + KDBP[DBP])
GC haplotype and diplotype-corrected free 25(OH)D concentrations were calculated using
diplotype specific binding constants according to Powe et al. (2013) and Johnsen et al.
(2014), respectively (Table 6).
Table 6. Affinity constants between 25(OH)D and albumin, DBP, and different GC haplo-and
diplotypes.
Affinity constants
Albumin 6 x 105
DBP 7 x 108
Haplotype GC 1S 0.60 x 109
Haplotype GC 1F 1.12 x 109
Haplotype GC 2 0.36 x 109
Diplotype GC 1S/1S ௗîௗ108
Diplotype GC 1S/2ௗ 4.8ௗîௗ108
Diplotype GC 1F/1F 11.2ௗîௗ108
Diplotype GC 1F/1S 8.6ௗîௗ108
Diplotype GC 1F/2 7.4ௗîௗ108
Diplotype GC 2/2 3.6ௗ[ௗ108
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4.2.5 Skeletal measurements
In Study I,  BMD, BMC and bone area were measured with DXA (Hologic Discovery A,
pediatric software, version 12.4) from the lumbar spine (LS) (L1-L4), total hip, and whole
body (WB).The measurement protocol is described in detail in Pekkinen et al. 2012.
Volumetric BMD and bone geometry were measured proximally at 4% and 66% from the
distal end of the non-dominant radius with pQCT (XCT-2000; Stratec, Pforzheim, Germany)
in a group of 175 subjects (104 girls, 71 boys). Total, trabecular, and cortical bone were
measured and BMC, total bone (TB), cross-sectional area (CSA), and SSI were calculated.
The DXA values were also transformed into Z-scores by using equipment-specific age- and
sex-adjusted reference data for US Caucasian children and in pQCT according to references
reported in the papers of Rauch et al. (2005) and Rauch & Schoenau (2008).
In Study III the distal sites of the non-dominant radius and left tibia were scanned at 4% and
5% from the distal endplate, respectively. The shaft sites of the radius and tibia were scanned
at 30% from the distal endplate. The measurement protocol is described in detail in
Laaksonen et al. (2010). The measured bone parameters were trabecular density (TraD) from
the distal radius and tibia and cortical density (CorD) from the radial and tibial shaft sites.
Furthermore,  cortical  strength  index  i.e.  ratio  of  cortical  bone  area  to  total  bone  area
(CSI=CorA/TotA) was calculated. The in vivo coefficients of variation (CV %) for the radius
were 1.6% for the TraD at the distal site and 3.2% for the CorD 0.5% at the shaft site. The
corresponding CV%s for the tibial traits were 0.5% and 0.6%.
4.3 Statistical analyses
The data are reported as means with standard deviations (SDs) or standard errors (SEs).
Hardy–Weinberg equilibrium of the GC genotypes in Studies I and II was tested with Chi-
square test. In Study I, association of variables was tested with Pearson correlation and if
outliers were detected, Spearman correlation was used instead. Linear regression analyses
were performed to determine the factors  associated with bone traits  measured with DXA
and/or pQCT in children and adolescents using GC genotype and other selected independent
variables. The relationship between GC genotypes and PTH was analysed only in the School
based study to avoid bias of different PTH assays in the two groups (Optiford and School
based study). Partial correlation was used to demonstrate the association after controlling for
confounding factor(s). Associations between GC genotype, 25(OH)D and PTH were
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analysed with analysis of covariance (ANCOVA) with relevant covariates. Test for linear
trend was performed by using contrast analysis. Simple regression analysis in the whole
study population was first performed to screen potential predictors for bone traits and a
multivariate linear regression model was used to identify significant predictors. In regression
analysis, GC genotype was used as a dummy variable (grouped into 0 (GC 1/1) and 1 (GC
1/2, GC 2/2)).
In Study II ANCOVA analysis was used to test variation among the GC genotypes in total,
free, bioavailable, and genotype-adjusted 25(OH)D concentrations using relevant covariates.
Also the variation between the GC genotypes and DBP concentrations and between the GC
genotypes and PTH were tested with ANCOVA. Tests for linear trend among the genotypes
in the 25(OH)D, PTH, and DBP concentrations were conducted using contrast analysis. In
this analysis, the three genotypes of the SNP 4588 were coded as í1, 0, and 1.
In Study III, the correlation between variables of interest was tested with Pearson correlation.
Background characteristics between the three BMI groups were compared with ANOVA.
The difference between the BMI groups in total, free and bioavailable 25(OH)D, PTH, and
DBP concentrations was tested with ANCOVA using relevant covariates.  Post-hoc
comparisons were made with Bonferroni correction. To determine the factors associated
peripheral bone traits, a backward regression analysis was performed for men and women
separately using selected independent variables.  The model with the largest adjusted
coefficient of determination (R2) is presented in the results.  Only the bone traits independent
of body size were used in the analysis.
Statistical analyses were conducted with PASW 18.0 (Study I), PASW 18.0.2 (Study II) and
SPSS24 (Study III). P-value<0.05 was considered significant.
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5 RESULTS
5.1 Background characteristics of subjects (I-III)
5.1.1 Children and adolescents (I)
Baseline characteristics in girls and boys in three GC genotype groups are presented in Table
7. The relative weight of the subjects was above 20% (=௘overweight) in 31 subjects and above
40%  (=௘obese)  in  7  subjects.  Vitamin  D  and  Ca  intakes  were  in  line  with  the
recommendations at the time (Nordic Nutrition Recommendations 2004) but compared with
the current recommendations of  10 μg/d (Nordic Nutrition Recommendations 2012),
vitamin D intake was lower than recommended in girls. Of the study population, 67% had
25(OH)D concentration below 50 nmol/L (68% of girls, 69% of boys). There was a negative
correlation between 25(OH)D and month of sampling: the 25(OH)D concentrations were
higher later in autumn than early in spring (r௘ ௘í0.184, P௘ ௘0.005), PTH correlated negatively
with 25(OH)D (r௘ í0.166, P=௘0.022) after controlling for Ca intake.
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5.1.2 Adults (II)
Background characteristics of subjects according to GC genotypes in Study II are presented
in Table 8. The mean total vitamin D intake was 15.1 ȝg/d and intake from supplements was
7.2 ȝg/d. The mean Ca intake was 1253 mg/d and intake from supplements 87 mg/d. The
daily vitamin D and Ca intakes (including supplements) were in line with Nordic
recommendations (Nordic Nutrition Recommendations 2012). Women and men differed
significantly in height, weight, serum albumin concentrations and BMI (P<0.001-0.002).
There was also a difference between genders in history of smoking and amount of physical
activity (P=0.013 and P<0.001). The mean 25(OH)D concentration in the total population
was 56 nmol/L and the mean PTH concentration 54.6 ng/L. The mean DBP concentration
was 368 mg/L. There was a negative correlation between PTH and total 25(OH)D
(r í0.235, Pௗௗ0.001). Negative correlations were also observed between free and
bioavailable 25(OH)D and PTH (r í0.223, P< 0.001; r í0.217, P<ௗ0.001). Total 25(OH)D
correlated negatively with BMI (r í0.173, P<0.001).
Table 8. Background characteristics of subjects according to GC genotypes (II).
ANOVA, values are shown as means (± SD). *at least one cigarette per day for six months
Variable GC1/1 GC1/2 GC2/2
N 386 192 28 P
Age (years) 42.0 (2.9) 42.0 (2.8) 42.0 (2.7) 0.969
Height (cm) 1.70 (0.92) 1.70 (0.93) 1.68 (0.72) 0.543
Weight (kg) 77.0 (16.7) 75.7 (14.9) 70.0 (13.7) 0.106
BMI (kg/m2) 26.8 (5.3) 26.2 (4.4) 24.8 (4.1) 0.194
Ca intake (mg/d) 1234 (515) 1306 (571) 1150 (411) 0.173
Vitamin D intake (μg/d) 14.9 (13.0) 15.0 (13.6) 17.1 (15.2) 0.711
25(OH)D (nmol/L) 56.8 (19.7) 53.2 (17.9) 57.3 (20.0) 0.095
Free 25(OH)D (pmol/L) 12.3 (5.10) 11.9 (4.6) 13.4 (4.70) 0.330
PTH (ng/L) 54.9 (24.4) 55.3 (26.5) 45.8 (17.0) 0.156
DBP (mg/L) 373 (89.0) 366 (88.1) 326 (64.6) 0.038
Albumin (g/L) 43.6 (2.97) 43.8 (3.08) 44.3 (2.78) 0.365
Physical activity (min/week) 475 (391) 501 (344) 438 (266) 0.587
History of regular smoking*(%) 44 51 36 0.762
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5.1.3 Obese adult subjects (III)
Background characteristics of women and men in BMI groups are presented in Table 9.
Obese women had lower vitamin D intake than normal-weight women, but calcium intake
did not differ between the groups. Obese women were physically less active and they smoked
more than normal-weight women. In obese men, vitamin D and calcium intakes were higher
and they smoked more than normal-weight men. Vitamin D intake reached the current
recommendations of the Nordic countries (10 ȝg/d) (Nordic Nutrition Recommendations
2012) in all groups.
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5.2 Genotype and allele distributions of GC SNP’s (I and II)
The genotype and allele distributions in Studies I and II are described in Table 10. In Study
I, six GC diplotypes were identified: 1S/1S, 1S/2, 1F/1F, 1F/2, 1S/1F, and 2/2.  Because of
only a small number of subjects among some of the diplotype groups, only the data of SNP
rs4588 genotypes were further analysed. The most common GC genotype was 1/1 and the
rarest  2/2.   In  Study  II,  the  same  six  diplotypes  were  detected  and  there  were  also  a  few
individuals with undetectable genotypes. Three common haplotypes were found: GC1S,
GC1F, and GC2. In Study II, the distribution of the third SNP rs705124 was 61% genotype
1, 34% genotype 2, and 5% genotype 3 (data not shown). The genotype distributions were
in compliance with Hardy–Weinberg equilibrium in both studies.
Table 10. Distribution of the GC SNPs in Studies I and II
Study I Study II
Genotypes % %
GC1/1 68 64
GC1/2 26 31.5
GC2/2 5.6 4.5
Diplotypes
GCS/1S - 47
GC1S/2 - 25
GC1F/1F - 2
GC1F/2 - 6
GC1F/1S - 16
GC2/2 - 4
Haplotypes
GC1S - 88
GC1F - 3.7
GC2 - 8.5
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5.3. 25(OH)D and PTH concentrations among GC genotypes
(I, II)
5.3.1 Children and adolescents (I)
After adjustment with vitamin D intake, PTH, study group, and month of sampling,
25(OH)D concentrations differed significantly among the genotypes being highest in GC1/1
and lowest in GC2/2 (P௘ ௘0.001, ANCOVA) (Figure 5A). In pairwise comparison, only the
difference between genotypes GC1/1 and GC1/2 was significant (P௘ ௘0.003). There was thus
a negative linear trend among the three genotypes (P=0.025). When adjusted with Ca intake,
25(OH)D and month of sampling, PTH concentration was significantly higher in GC 1/1
than in the other genotypes (Figure 5 B). Similarly, in individuals with the genotype GC1/2
the 25(OH)D concentration was intermediate and they also had intermediate PTH
concentration, and in individuals with the GC2/2 genotype, who had the lowest 25(OH)D
concentration, the lowest PTH concentration (P௘ ௘0.028, linear trend P௘ ௘0.012) was seen.
Figure 5 A-B Association of GC genotypes with 25(OH)D (A) and PTH (B) concentrations in
children and adolescents in Study I. Results are shown as estimated meansௗௗSE, ANCOVA.
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5.3.2 Adults (II)
25(OH)D concentrations differed among the SNP rs4588 genotypes (P=0.031, ANCOVA)
and also between the six diplotypes (P=0.033, ANCOVA). PTH, vitamin D intake, sunlight
exposure,  BMI  and  gender  were  used  as  covariates  (Figure  5  C).  Similarly,  PTH
concentrations differed between the diplotypes (P=0.040), when adjusted for 25(OH)D,
calcium intake and sex (Figure 5 D). Among the haplotypes there was no significant
difference (P=0.078). However, a linear trend was emerged (P=0.044, data not shown).
Among the SNP rs705124 genotypes, a difference between PTH concentrations was
discovered (P=0.016, ANCOVA, data not shown).
5.4 Association of GC diplo/haplotype with DBP, total, free
and bioavailable 25(OH)D (II)
DBP concentrations differed among the diplotype and haplotype groups (Pௗ ௗ0.039 and
P=0.039, respectively, ANCOVA), one of the lowest concentration being in subjects with
the GC2/2 genotype (Figure 5 E).There was no difference in free and bioavailable 25(OH)D
concentrations among the GC diplo-/haplotypes. However, in genotype-adjusted
concentrations the highest concentration of free 25(OH)D was found in diplotype 2/2
(P<0.001, ANCOVA) (Figure 5 F), and haplotype GC2 (P<0.001, data not shown). Also
bioavailable 25(OH)D concentrations differed significantly among the genotypes (P<0.001)
and similarly, highest concentration was found in genotype GC2/2. (Figure 5 G).
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5.5 Total, free and bioavailable 25(OH)D concentrations
between BMI groups (III)
Total, free, and bioavailable 25(OH)D correlated inversely with BMI in women (r=-0,20; -
0,21; -0,23, respectively, P<0.001) and in both genders analysed together (r=-0.15; -0.19; -
0.19; respectively, P<0.001), but not in men. In women, 25(OH)D concentrations did not
differ among the BMI groups (Figure 6 A). In men, 25(OH)D was lower in obese men than
in their normal-weight peers (P=0.024) but no differences emerged between normal-weight
and overweight groups or overweight and obese groups. Similarly, when both genders were
analysed together, obese subjects had lower 25(OH)D than normal-weight subjects
(P=0.003). There was also a significant difference between overweight and obese groups
(P=0.048). Free and bioavailable 25(OH)D concentrations were lower in obese women
(P<0.008 and <0.003, respectively) (Figures 6 B and 6 C). Also in men, free and bioavailable
25(OH)D were lower in obese subjects (P=0.044 and 0.032, respectively). When both
genders were analysed together, a significant difference remained (P<0.001). There was also
a significant difference between overweight and obese subjects in free and bioavailable
25(OH)D. No differences was seen between normal-weight and overweight group or
overweight and obese groups in women and men analysed separately.
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5.6 PTH and DBP concentrations between BMI groups (III)
Total and free 25(OH)D correlated negatively with PTH in both men (r= -0.179, P= 0.013
and r= -0.159 P=0.042, respectively) and women (r= -0.232, P<0.001, and r= -0.211,
P<0.001, respectively). Bioavailable 25(OH)D correlated negatively with PTH in women
(r=-0.207; P <0.001), but in men the correlation did not reach significance. DBP correlated
positively with BMI when men and women were analysed together (r=0.363, P=0.025). In
women, DBP and PTH correlated positively with BMI (r=0.129, p=0.016; r=0.181, P<0.001,
respectively). In women, PTH was higher in obese subjects than in normal-weight subjects
(P=0.045) (Figure 6 D). In men, the difference was not significant. When both sexes were
analysed together, the difference was significant (P=0.047). Obese women had higher DBP
concentration than normal-weight women (P=0.008) (Figure 6 E). In males, DBP
concentration did not differ among BMI groups. When both sexes were analysed together,
DBP was higher in obese subjects than in normal-weight subjects (P=0.004). There was no
difference in PTH or DBP concentrations between normal-weight and overweight subjects
or overweight and obese subjects.
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5.7 Associations of GC genotypes with skeletal outcomes (I)
The unadjusted values of bone parameters measured with DXA among genotypes GC
1/1 and the combined genotypes GC 1/2 and 2/2 in children and adolescents are
presented  in  Table  11  (ANOVA).  There  was  no  differences  in  bone  traits  among  the
genotypes in girls and boys. However, in regression analysis, GC genotype together with
weight, age and pubertal stage were significant determinants of LS BMC in both boys
and girls, as well as height in girls. Also when girls and boys were analysed together,
GC genotype remained a significant determinant of LS BMC. In girls, GC genotype
together with height, 25(OH)D concentration, pubertal stage, and age were significant
determinants of total hip BMC. In addition, weight, 25(OH)D concentration, GC
genotype and PTH in girls determined SSI. The results of linear regression analysis on
determinants of bone characteristics in groups defined by sex are presented in Tables 12
and 13.
When the bone variables were transformed into Z-scores, GC genotype was a significant
determinant  of  LS  BMC  Z-score  in  girls  and  weight,  25(OH)D  concentration,  GC
genotype and physical activity were significant determinants of SSI Z-score when
genders were combine
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5.8 Obesity and bone (III)
5.8.1 Differences in bone traits between BMI groups
Mean ±SD bone traits and comparison between normal-weight (NW), overweight (OW)
and obese (OB) subjects are shown in Table 14. Trabecular density in obese women was
6.3% higher in distal radius and 6.6% higher in the distal tibia than the corresponding
figures in normal-weight women (P=0.004 and P<0.001, respectively). In addition, CSI
was 12.5% higher in obese women than in normal-weight women (P=0.022). Cortical
density was 1.7% and 0.9% lower in obese women in the shaft sites of the radius and
tibia, respectively (P<0.001; P=0.008, respectively) (ANOVA). In obese men, trabecular
density was 3.9% higher in the distal radius and 12% higher in the distal tibia than the
corresponding figures in normal-weight men (P=0.012 and P<0.001, respectively)
(ANOVA). Distal tibia CSI was 11% higher in overweight and obese group compared to
normal-weight  and tibial  shaft  CSI 1% higher  in  obese and 2 % higher  in  overweight
group (P=0.029; P=0.019, respectively). Tibial shaft cortical density was 1% lower in
obese men than in normal-weight men (P<0.001).
5.8.2 Differences in bone turnover markers between the BMI groups
Mean values of bone turnover markers and comparison between normal-weight,
overweight and obese subjects are presented in Table 14. CTX and PINP concentrations
were lower in obese women than in normal-weight women after adjusting with age. Also
PINP and osteocalcin were lower in obese women. In men, CTX and osteocalcin
concentrations were lower in obese subjects than in normal-weight subjects.
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5.8.3 Associations of total, free and bioavailable 25(OH)D with bone traits
in BMI groups
Standardized ȕ-coefficients and R2 -values in backward linear regression models for
determinants of pQCT-bone traits in obese women are presented in Table 15.  25(OH)D,
free and bioavailable 25(OH)D were included as independent variables in regression
models 1, 2 and 3, respectively. In model 1, there was a negative association of 25(OH)D
with distal radius TraD and tibial shaft CSI. Furthermore, in model 2, free 25(OH)D was
a negative determinant of distal radius CSI and tibial shaft CSI and radial shaft CoD. In
model  3,  bioavailable  25(OH)D was  a  negative  determinant  of  distal  radius  CSI,  and
tibial shaft CSI and radial shaft CorD. In normal-weight and overweight women, no
associations were found between bone traits and 25(OH)D, free, or bioavailable
25(OH)D concentrations. In normal-weight and obese men, no associations were found
between 25(OH)D concentrations and bone traits. In overweight men, a positive
association emerged between total 25(OH)D and distal radius CSI (data not shown).
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6 DISCUSSION

6.1 Main findings 

In both children and adolescent in Study I as well as in middle-aged men and women in
Study II, an association of 25(OH)D concentration with GC gene polymorphisms was
found.  In addition, GC genotype was associated with DBP concentrations and with free
and bioavailable 25(OH)D concentrations in Study II. GC genotype was associated with
BMD and bone strength measured with pQCT/DXA in Study I. In obese middle-aged
subjects,  lower  total,  free  and  bioavailable  25(OH)D  and  higher  DBP  and  PTH
concentrations than in normal-weight subjects were presented (Study III). Total, free and
bioavailable 25(OH)D concentrations were associated with bone traits in obese subjects
and markers of bone metabolism differed between obese and normal- weight subjects.
6.2. GC genotype distribution
Three GC genotypes: 1/1, 1/2 and 2/2 and six diplotypes: GC1S/1S, GC1S/2, GC1F/1,
GC1F/2, GC1F/1S, and GC2/2 were detected in Studies I and II. Unfortunately in Study
I, the number of subjects was too low to conduct statistical analyses of diplotypes. The
genotype distribution in children and adolescents in Study I and in adults in Study II was
similar. Three different haplotypes were detected in Study II, corresponding to the three
GC protein isoforms GC1S, GC1F and GC2. The genotype distribution in Studies I and
II resembles the genotype distribution of GC gene reported in Finnish genome bank
databases (Sequencing Initiative Suomi=SISu) (total 10 481 samples). The genotype
distribution in SISu is GC 1/1=63 % (N=6665), GC1/2=32 % (N=3406), GC 2/2 =3,9 %
(N=410).
The frequency of different DBP isotypes varies by ancestry; GC 1F/1F is most common
in West Africans and African Americans and least common in Caucasians (Kamboh &
Ferrel 1986). Finns have been shown to be genetically distant from Central Europeans
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or even from the inhabitants of other Nordic countries (Salmela et al. 2011). For example
in a study conducted in Danes, the distribution of the GC phenotypes GC1S/1S,
GC1S/1F, Gc1F/1F, GC1S/2, GC1F/2 and GC2/2 was 32%, 19%, 2.9%, 33.4%, 5.2%
and 7%, respectively (Lauridsen et al. 2005). For our knowledge, there is no published
data on the GC diplotype distribution in Finns.
6.3 Total, free and bioavailable 25(OH)D, PTH and DBP in
GC genotypes
DBP variants have been shown to have affinity differences to 25(OH)D and 1,25(OH)D
due to the differences in protein configuration. GC1F has the highest affinity and GC2
the lowest (Arnaud & Constans 1993). The same hierarchy has been found in serum DBP
concentrations (Lauridsen et al. 2001). In children and adolescents of Study I and in
adults of Study II, serum 25(OH)D concentrations differed considerably among the GC
genotypes, the concentration being highest in genotype GC 1/1 and lowest in GC 2/2.  In
diplotypes, 25(OH)D concentration was lowest in 1S/1F and highest in 1F/2. The
difference between 25(OH)D concentrations was significant between diplotypes 1S/2
and 1F/2. The study by Lauridsen et al. (2001) was one of the first to report the common
SNP’s rs4588 and rs7041 to be associated with 25(OH)D concentrations, and several
studies, including Studies I and II, have since confirmed this finding (Lauridsen et al.
2005, Sinotte 2009, Gozdzik et al. 2011, Carpenter et al. 2013, Nissen et al.  2014, Powe
et al. 2014, Petersen et al. 2017). The findings have been similar across studies, with the
C allele (ancestral allele) of rs4588 associated with higher 25(OH)D concentrations.
Similarly in SNP rs7041, the findings have been consistent with lower 25(OH)D with
the T allele (ancestral allele).
Nissen et al. (2014) found that six SNPs in the GC gene (rs4588, rs16846876, rs2282679,
rs12512631, rs17467825, and rs842999) were associated with 25(OH)D concentrations
in Danes. Recent longitudinal study including 642 healthy Danish children, investigated
associations between vitamin D-dependent SNPs and 25(OH)D concentrations (Petersen
et al. 2017). They found minor alleles of GC rs4588 and rs7041 to be associated with
lower  serum  25(OH)D  concentrations  across  the  seasons.  In  a  study  by  Powe et al.
(2014), genetic polymorphism in the GC gene explained almost 10% of the variation in
25(OH)D concentrations.
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In Studies II and III, one aim was to test whether the unbound fractions of vitamin D
were more biologically active than the bound 25(OH)D. The concentrations of free and
bioavailable 25(OH)D were calculated with a previously published formula (Bikle et al.
1986, Powe et al.  2014).  Furthermore,  an  adjustment  was  made  for  the  free  and
bioavailable 25(OH)D concentrations with haplotype- and diplotype-specific binding
constants (Arnaud & Constans 1993, Johnsen et al. 2014) in Study II. Free and
bioavailable concentrations differed significantly among the GC haplotypes and
diplotypes  after  the  adjustment.  Also  in  a  Norwegian  study,  calculated  free  and
bioavailable concentrations changed considerably, when they were adjusted for DBP
binding constants (Johnsen et al. 2014).
Due to the inverse association between 25(OH)D and PTH found in numerous studies,
PTH concentration has been suggested for use as a reference for optimal vitamin D status
(Sai et al. 2011). As expected, there was an inverse correlation between 25(OH)D and
PTH in both children and adolescents in Study I and in adults in Study II.  In contrast to
general  associations,  in  Study  I,  both  25(OH)D  and  PTH  were  lowest  in  the GC2/2
genotype.
In  Study  II,  the  similar  trend  as  in  Study  I  was  seen: GC2/2, with the second lowest
25(OH)D concentrations among diplotypes, had the lowest PTH concentrations.
Interestingly, the free and bioavailable 25(OH)D concentrations were high in these
groups as well, which could be one explanation for the low PTH concentrations.
It  has  been  shown that  vitamin  D  prohormones  can  suppress  PTH secretion  from the
parathyroid glands through the VDR receptor (Ritter et al. 2011). Because the amount
of free 25(OH)D was higher in genotype GC2/2,  there  could  be  more  free  forms  of
25(OH)D which could suppress PTH secretion from the parathyroid glands. Carpenter
et al. 2013 observed that GC genotype did not have an influence on the relationship
between 25(OH)D and PTH. However, they did not investigate the association of PTH
with GC genotypes.
DBP concentrations varied significantly among the GC genotypes as well as among the
haplotypes in Study II, the lowest DBP concentration being in genotype GC2/2 and the
highest in GC1/1. In diplotypes, the highest concentration was in GC1F/1F and the
lowest in GC2/2. However, the only significant difference was between GC1F/2 and
GC2/2. Several studies have found variation in DBP concentrations among the common
GC genotypes (Lauridsen et al. 2001, Nissen et al. 2014, Wilson et al. 2015). In a study
of African American and Caucasian American subjects, DBP concentration was highest
in GC1S homozygotes, intermediate in GC2, and lowest in GC1F  (Wilson et al. 2015).
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According to a Danish study, GC2 homozygotes had lower DBP concentrations than the
other genotypes, which is in line with the results of Study II (Lauridsen et al. 2001).
Vitamin D intake and 25(OH)D concentrations
In Study I, 67 % of the children and adolescents had 25(OH)D concentration rather low;
below 50 nmol/L. Vitamin D intake from food and supplements was quite low also,
especially in girls (< 10 μ/day). The explanation for this is probably the fact that the
study data was collected between the years 2001-2002 (Optiford) and 2007-2008, when
the fortification of foodstuffs with vitamin D was not yet at the same level as at the
present. The recommendations for vitamin D fortification were doubled in 2010 for milk
and spreads. Also the recommendations for total vitamin D intake were increased from
7.5 to 10 μg/day in 2014. In adults (Study II and III), mean serum 25(OH)D
concentration was 56 nmol/L. The mean vitamin D intake from food and supplements
was 16 μg/day and there was a large variation among the subjects. The PHOMI-study
was conducted in spring 2010, when the fortification of fluid milk products and spreads
was already more common. The higher vitamin D intakes and 25(OH)D concentrations
in the adults are most likely due to fortification and increased use of supplements.
6.4 Relationship between GC genotype and bone parameters
in children and adolescents
Several studies have examined GC gene polymorphism and bone health. Most of them
have concentrated on the common SNPs rs4588 and rs7041 (Lauridsen et al. 2004, Al-
Oanzi et al. 2006, Fang et al. 2009, Xu et al. 2010), whereas some have investigated
other polymorphisms in the GC gene (Papiha et al. 1999, Ezura et al. 2003).  The
majority of studies have focused on adults. Study I is novel in evaluating the association
between GC genotype and bone health in children and adolescents. When the mean bone
traits  between  the  genotypes  in  girls  and  boys  were  compared  with  ANOVA  and
ANCOVA, the only difference was found in total hip BMC in boys. The group with the
82
combined GC1/1 and GC2/2 genotype had slightly lower BMC in total hip.  Also in
boys, GC genotype was a negative determinant of lumbar spine BMD and whole body
BMD.  In  girls,  genotype  was  a  negative  determinant  of  the  bone  strength  and  strain
index, SSI.  Low SSI, volumetric BMD, cortical area and areal BMD can contribute to
increasing fracture risk in children (Kalkwarf et al. 2011). Also other studies have
reported association of GC polymorphism with bone strength indices and fracture risk.
In a study on Japanese postmenopausal women, SNPs within the GC gene were
associated with BMD of the radius measured with DXA (Ezura et al. 2003). The authors
concluded that several SNP’s in the GC gene could act together and increase the
osteoporosis risk.  In a study by Lauridsen et al. (2004), a significant difference in BMD
in postmenopausal women among GC phenotypes was found. DBP polymorphism has
been shown to be associated with fracture risk in men from United Kingdom (Al-Oanzi
et al. 2006). Fang et al. (2009) reported an association between haplotype GC1S and
fracture risk. The risk was stronger when dietary Ca intake was low.  In study I, Ca intake
was quite high, but there was still an association between SSI and genotype. Xu et al.
(2010) reported that there was an association between compression strength index and
GC polymorphism in Caucasian men.
The mechanism how GC genotype affects bone metabolism is not clear. Lauridsen et al.
2004 suggested that the association they found between GC genotype and fracture risk
could arise from GC-MAF formation. Because DBP concentration differs between DBP
genotypes, there would be more substrate for GC-MAF formation in certain genotypes.
Additionally, they found that osteoclast formation rate was higher.  Another reason could
be different glycosylation of DBP isoforms because the formation of GC-MAF requires
removal of the glucose residuals (Lauridsen 2004). Unfortunately DBP concentration
were  not  measured  in  Study  I.   It  is  possible  though  that  one  reason  for  the  negative
association of GC polymorphism with bone traits found in Study I could be due to a
difference in DBP concentrations among different genotypes leading to differences in
GC-MAF formation and osteoclast activation (Fang et al. 2009).
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6.5 Vitamin D metabolism and bone in obese subjects
25(OH)D concentrations are  lower in obese people and have been shown to correlate
inversely with BMI (Bell et al. 1985, Konradsen et al. 2008). Reasons for lower
25(OH)D could  be  larger  volume  of  fat  tissue  as  well  as  other  tissues  i.e.  blood  and
muscles, leading to less vitamin D for 25(OH)D synthesis in the liver (Liel et al. 1988,
Wortsman et al. 2000, Drincic et al.  2012).  Studies  have  revealed  that  the  rise  of
25(OH)D in  the  circulation  after  UV exposure  is  weaker  in  the  obese,  and  therefore,
these subjects may need a higher vitamin D dosage than normal-weight subjects to reach
the same concentration of 25(OH)D in blood (Wortsman et al. 2000, Drincic et al. 2012).
In Study III, 25(OH)D concentrations differed significantly among the BMI groups. The
association was found in men and in the total group (men and women together). Also in
women there was a similar trend in Study III. The lowest 25(OH)D concentrations were
found in obese subjects. Although it is well established that obese individuals have lower
25(OH)D, few studies have examined whether there are also differences in free and
bioavailable 25(OH)D. Furthermore, the results of the studies have been contradictory
partly because the methods have varied from estimated values (Karlsson et al. 2014) to
direct measurement (Holmlund-Suila et al. 2016, Walsh et al. 2016) and are therefore
not completely comparable. A Swedish study compared obese and normal-weight
women and discovered that obese women had lower total and calculated free 25(OH)D
than in normal-weight women (Karlsson et al. 2014). Walsh et al. (2016) measured free
and bioavailable 25(OH)D concentrations directly in obese women and men of various
age  groups  in  United  Kingdom.  In  their  study,  25(OH)D was  lower  in  the  obese  and
overweight groups than in normal-weight groups only in the fall and spring. However,
there was a negative correlation with whole-body fat mass in all seasons. In Study III,
25(OH)D was lower among obese subjects only in men or when men and women were
analysed together. Study III was conducted in winter, when the cutaneous synthesis of
vitamin D is marginal in Finland. Walsh and colleagues (2016) suggested that the
stronger difference between obese and normal-weight subjects in the fall and spring
could be explained by the attenuated rise of 25(OH)D in the obese. Consequently, the
lack of vitamin D measurements from summer months in Study III may have narrowed
the range of 25(OH)D data and reduced the strength of the observed associations.
In study III we discovered that obese subjects had higher DBP concentrations than
normal-weight subjects. Taes et al. (2006) found that DBP correlated positively with
BMI and leptin concentrations.  They also observed differences in fasting glucose
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concentrations between DBP phenotypes and suggested that the relation DBP-fat mass
could have influenced glucose handling of these subjects. In vitamin D deficiency, DBP
could stabilize vitamin D concentrations with positive effects on glucose handling.
Karlsson et al. (2014) compared 22 to 45-year-old obese and normal-weight women and
found that obese individuals had higher DBP concentrations. They suggested that
because oestrogens are known to increase DBP concentrations, higher concentrations of
free oestrogen in obesity might have an effect on hepatic DBP production. They also
suggested that IL-6 could be behind the higher DBP concentration in obese subjects,
since in vitro IL-6 has been shown to increase hepatic DBP production (Guha et al. 1995)
and IL-6 is elevated in obesity (Bastard 2000). Walsh et al. (2016) found no difference
in DBP concentrations between obese and normal-weight subjects but DBP
concentrations correlated inversely with BMI. Also in a Finnish study, DBP
concentrations did not differ between obese and normal-weight young adults (Holmlund-
Suila et al. 2016). Oral oestrogens and pregnancy are known to increase DBP
concentrations in the circulation. Higher concentrations of free oestrogen in obesity
could possibly have an effect on hepatic DBP production and be one explanation for the
higher DBP concentration in obese subjects (Karlsson et al. 2014).  Some studies have
suggested that insulin might suppress the production of DBP. In these studies, DBP was
lower in obese compared to normal- weight subjects and there was an inverse
relationship between insulin levels and DBP, even when corrected for adiposity (Ashraf
et al. 2014, Miraglia del Giudice et al. 2015). Unfortunately, in Study III we were not
able to determine insulin resistance of the subjects. Miraglia del Giudice et al.  (2015)
found that obese insulin resistant children had 25(OH)D concentrations similar to those
of normal-weight children due to reduced concentration of DBP.
Also DBP genotype has been demonstrated to associate with obesity although the
biological mechanism for this remains obscure (Jiang et al. 2007, Almesri et al. 2016).
In general,  DBP genotype can influence the measured DBP concentrations as  well  as
DBP’s ability to bind 25(OH)D. In Study II, we found that GC genotype was associated
with DBP, PTH, and vitamin D concentrations. Due to rather small group sizes in Study
III, it was not possible to examine the role of GC genotype in vitamin D metabolism of
obese subjects.
As expected, an inverse association between 25(OH)D and PTH was found in Study III.
Furthermore, PTH concentrations differed between the BMI groups, but only in women
or  when  the  sexes  were  combined.   Contrary  to  the  results  of  Study  III,  Walsh et al.
(2016) did not find differences in PTH concentrations among the BMI groups and PTH
did not correlate with BMI in either sex. They suggested that the relationship between
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25(OH)D and PTH may be altered in obesity. There are also studies where body weight
was a strong predictor of PTH, but 25(OH)D had little or no relation with PTH. Obese
young Finnish adults had lower total and measured free 25(OH)D and slightly higher
PTH than their normal-weight peers, and free 25(OH)D was associated with obesity-
related parameters (Holmlund-Suila et al. 2016).
Studies  on  the  association  of  total  or  free  25(OH)D  with  bone  have  revealed
contradictory results. Study III is the first study to examine the direct association of free
and bioavailable 25(OH)D with several bone traits measured with pQCT. Obese men
and women had higher trabecular density and CSI but slightly lower cortical density. We
found that total 25(OH)D was a significant but weak negative determinant of trabecular
density of the distal radius, and free and bioavailable 25(OH)D were negative
determinants of tibial shaft CSI. Free and bioavailable 24(OH)D were negatively
associated with cortical density of the radial shaft. In normal-weight women or men, no
significant association was found between vitamin D metabolites and bone traits.
Furthermore obesity was associated with lower concentrations of bone turnover markers
in both men and women.
In a study by Johnsen et al. (2014), free and bioavailable but not total 25(OH)D,
correlated with BMD, and when an adjustment with GC genotype-specific constants was
made the association improved.  Jemielita et al. (2016) found racial differences in the
association of 25(OH)D with bone. Total and calculated free 25(OH)D were positively
associated  with  bone  traits  measured  with  pQCT  in  black  subjects  but  not  in  white
subjects. However, to determine DBP concentration they used a monoclonal antibody-
based method, which has been shown to give false results, especially among dark-
skinned populations (Bouillon et al. 2014).
Walsh et al. (2016) found that whole-body, hip, and spine BMD as well as distal radius
and tibia trabecular density were higher in the obese and overweight groups than in the
normal-weight group. Bone turnover was also higher in obese subjects, contrary to the
results of Study III. They suggested that lower 25(OH)D in obesity could be a sign of
vitamin  D  deficiency,  but  the  positive  skeletal  effects  of  obesity,  such  as  increased
oestrogen synthesis, could reverse the effect on bone. However, women of Study III
were premenopausal and with sufficient oestrogen production from the ovaries. A
potential explanation for the negative associations of free and bioavailable 25(OH)D
concentrations with some bone traits in obese women could be altered vitamin D
metabolism due to higher DBP and lower free and bioavailable 25(OH)D. Obese women
were more frequent smokers and they exercised less than normal-weight women. Higher
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DBP concentrations in the obese could also mean greater GC-MAF production and
moreover osteoclast activation.
Obesity is associated with stronger bones and prevents osteoporosis and fractures,
particularly hip fractures (Johansson et al. 2014). One reason is greater body weight,
which creates additional loading on the weight-bearing skeleton. Also the large amount
of adipose tissue may produce more oestrogen which, in turn, has a major impact
especially on female skeleton (Järvinen et al. 2003). Excess weight in adolescence is
known to  be  associated  with  larger  bone  cross-section  and  to  modulate  also  BMD in
adulthood (Uusi-Rasi et al.  2012). However, the amount and intensity of physical
activity are the major determinants of bone loading (Weeks et al. 2008).
6.6 Evaluation of the studies
6.6.1. Study design, population, and sample size
The cross-sectional design of the studies allows only observation of the situation at a
specific time point and prevents determination of causality.
Because the data from Studies II and III originate from a study focusing on phosphorus
and bone, the power calculations were not based on vitamin D outcomes. When
examining bone traits, the genders must be analysed separately. In Studies I-III, the
proportion of boys/men relative to girls/women was much smaller. In Study I, almost 70
% of the subjects were girls, and in Studies II and III the proportion of women was
approximately 65%.
The study population of children and adolescents in Study I was rather challenging.
Firstly, the subjects were derived from two cohorts (Optiford study and School-based
study) collected over a wide time frame (2003-2008). Secondly, the age of the subjects
varied from 8 to 19 years. Especially when the data were divided into GC genotype
groups, puberty status in both girls and boys was not even in the groups. Genotype
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distribution was also uneven; the number of subjects was low, particularly in the rare
genotype GC 2/2 and in boys.
6.6.2 Methods
At  the  time  when  Studies  I  and  II  were  conducted,  there  were  no  Finnish  genotype
database and the CEU database (Northern Europeans from Utah) was used instead. Since
then, a database that covers the gene variation in the Finnish population has been
established.  Finland's gene pool has been shaped by several bottlenecks during
population history. SISu (http://www.sisuproject.fi/) was established in 2014 to build a
specific reference dataset of sequence variants in Finns. The current version covers SNPs
and indels from exomes of over 10 000 individuals sequenced in disease-specific and
population genetic studies. The Exome Aggregation Consortium (ExAC)
(http://exac.broadinstitute.org/) is an association of investigators seeking to aggregate
and harmonize exome sequencing data from a wide variety of large-scale sequencing
projects, and to make summary data available to the wider scientific community. The
genotyping was conducted with Real Time PCR using probes from Allogene (Study I)
and by using TaqMan chemistry on an automatic sequence-detection instrument (Study
II). In Study I, the common GC SNPs rs4588 and rs7041 were selected. These SNPs are
known to have variation and to be associated with 25(OH)D measures in other
populations. In Study II, SNPs covering the DBP gene region were selected from the
International HapMap Project database. The CEU population was used as a reference
when selecting the SNPs, again because no Finnish database existed at the time of the
study.
There are several methods for measuring 25(OH)D in serum, as described in the review
of the literature and the methods have developed considerably over the years. In this
thesis, the measurements were conducted with IDS ELISA (Studies II and III) and HPLC
(Study I). The Vitamin D External Quality Assessment Scheme (DEQAS) has revealed
considerable differences among different methods (both within and between
laboratories), raising concerns about the comparability and accuracy of different assays
and laboratories.
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At the time that the samples for Studies II and III were analysed (2010), the analysing
laboratory  was  in  the  process  of  completing  the  DEQAS  certificate  to  guarantee
reproducibility of analyses. The certificate was received in 2012.
LC-MS/MS analyses have shown that immunoassays display interference of
24,25(OH)2D, especially at higher 25(OH)D concentrations, yielding overly high
25(OH)D values (Malmström et al. 2017), whereas no interference with 25(OH)D
measurements  occurs  when using HPLC or  LC-MS/MS,  LC-MS/MS and HPLC can
measure 25-hydroxycholecalciferol (25(OH)D3) and 25-hydroxyergocalciferol
(25(OH)D2) separately. They also allow detection of other vitamin D metabolites such
as 24,25-dihydroxyvitamin D (24,25(OH)2D). Therefore, these two methods are
considered the gold standard for measurement of vitamin D metabolites.
Several studies have found that calculating free 25(OH)D overestimates the
concentrations relative to directly measuring free 25(OH)D (Schwartz 2014, Aloia et al.
2015, Lee et al.  2015, Alzaman 2016, Sollid 2016). The overestimation seems to be
higher in blacks and especially when using a monoclonal antibody–based assay for
measuring DBP (Bouillon et al. 2014, Aloia et al. 2015, Alzaman 2016). The
monoclonal antibody-based assay appears not to recognize the 1F allele in DBP, which
is common in African Americans, and therefore, several studies using monoclonal
antibodies in their DBP analyses are not reliable. The direct method for measuring
25(OH)D is, in any case, novel and unpredictable. There are some limitations when
calculating free and bioavailable 25(OH)D concentrations. First, the affinity constants
of DBP that Arnauld & Constans (1993) used in the calculation of free and bioavailable
25(OH) concentrations are derived from one individual’s human serum sample. It is not
known whether there are post-translational modifications of DBP that could affect its
affinity for vitamin D metabolites. Second, the GC affinity constant for 25(OH)D in the
literature varies widely (Bikle et al. 1986).  Furthermore, because the full sequence of
the DBP is not known, there might also be isoforms other than the common ones.
According to Arnauld’s analysis, binding affinity of these rarer isoforms may vary as
much as 12-fold (Arnauld & Constans 1993, Malmström et al. 2017). A certified method
for measuring total 25(OH)D and method using polyclonal antibodies in DBP
measurement makes the calculation of free 25(OH)D values in Studies II and III rather
reliable.
DXA is  the most  common method to assess  BMD and BMC, and it  is  considered the
gold standard in all age groups. However, it has several limitations. DXA measures areal
BMD, thus two dimensions, and not true volumetric density like pQCT. aBMD (g/cm2)
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consists of bone mass or BMC per bone area of a three-dimensional structure. Skeletal
growth in children leads to a much higher increase in volume than in bone area and
therefore, young children have proportionally larger area in relation to bone volume
compared with older children (Pezzuti et al. 2017). Minimal exposure to radiation
especially in children is also an advantage of pQCT-measurements. The use of pQCT in
bone measurements provides relevant data for trabecular and cortical BMD as well as
for bone geometry, size, and mass (Sievänen et al. 1998). In this thesis, several bone
traits were measured with pQCT in non-weight-bearing radius and weight-bearing tibia
in different age subjects (children and adolescents as well as adults. In Study I, the
skeletal  age  of  the  subjects  was  not  determined  at  the  time  when  the  studies  were
conducted, and therefore the only classification method was the puberty stage and age.
Extensive background data, including sunshine exposure, dietary intakes of vitamin D
and calcium, vitamin D intake from supplements, and collecting data on of physical
activity and measurement of several established biomarkers are strengths of this thesis.
In addition, there was a large population-based sample of both women and men in
Studies II and III. Recording the influence of bone-loading activity on bone traits and
history of physical activity in children and adolescents as well as in the adults, could
have provided important additional information for the bone analysis. Because weight
and height are strong determinants of bone size related traits (Uusi-Rasi 2010) and the
purpose was to study the other factors that may affect bone, only the bone parameters
that were independent of body size were included in the Study III. The measurement of
fat  percentage,  waist  circumference  or  body  composition  would  have  been  a  better
alternative for measuring obesity than BMI in Study III. Menopause was determined in
Studies II and III.
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7 SUMMARY AND CONCLUSIONS
At the time that Study I was conducted, it was the first study to examine the association
between GC genotype and bone health in children and adolescents. Based on the results
from Studies I and II, it can be proposed that 25(OH)D and PTH concentrations differ
among GC genotypes and that variation exists in BMD and bone strength among
genotypes in children and adolescents. Variation in 25(OH)D among genotypes suggests
differences in vitamin D utilization. In Study I, more associations between GC genotype
and bone traits were found in boys, although an association of GC with SSI was found
in girls. This may be due to gender differences in the phase of skeletal development and
also the low number of boys in the study. Based on the outcomes of Study I, it can be
concluded that DBP may be one factor taking part in bone mass accrual during
adolescence. However, the cross-sectional design prevented from establishing a causal
relationship between GC genotype, 25(OH)D, PTH, and bone accrual. In the future, DBP
polymorphism could be useful in detecting individuals who are more vulnerable to
vitamin D deficiency, especially while their skeleton is still developing.
The findings from Study II indicate that genetic polymorphisms of DBP and free
metabolites of 25(OH)D may be relevant when vitamin D status and vitamin D
metabolism are evaluated. These findings suggest that DBP genotype may influence
vitamin D metabolism through multiple pathways. The mechanism may be through
differences in plasma 25(OH)D directly suppressing PTH production and secretion in
the parathyroid gland or through differences in free 25(OH)D, which may modulate the
availability of 1,25(OH)D, suppressing PTH.  Further investigation of the effect of DBP
on free 25(OH)D is warranted.
The observed associations between obesity and total, free, and bioavailable 25(OH)D,
DBP, and PTH in Study III and similar results from previous studies suggest that obese
individuals differ from their normal-weight peers in vitamin D metabolism. Moreover,
there was negative association of free and bioavailable vitamin D metabolites with some
pQCT-measured bone traits in obese women. In the future, obesity and genetic
determinants of vitamin D should be taken into account to detect individuals susceptible
to vitamin D deficiency who could benefit from vitamin D supplementation.
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